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ABSTRACT 
Toxicities of sulfur-based drugs have been attributed to formation of highly 
reactive sulfur oxo-acids and depletion of glutathione by the formation of reactive 
metabolites. Metabolic activation of these sulfur centers to conceivably toxic reactive 
metabolites (RMs) that can covalently modify proteins is considered the initial step in 
drug-induced toxicity. Despite considerable effort and research, detection and 
characterization of these RMs during drug development and therapy remains a challenge. 
Methimazole (MMI) and 6-propyl-2-thiouracil (PTU) are two commonly used 
antithyroid, sulfur-based drugs. Though effective, these drugs are associated with 
idiosyncratic toxicity. PTU has acquired a black box warning and physicians are calling 
for its withdrawal. RMs resulting from bioactivation of these drugs have been implicated 
in the aforementioned adverse reactions. Unfortunately, isolating and detecting RMs 
using traditional analytical techniques has not been successful due to their high reactivity 
and short life span, typically less than a minute.  
Current approaches in drug metabolism studies use microsomal incubations to 
generate RMs, which are then trapped using nucleophiles. Antithyroid drugs, however, 
are known to deactivate enzymes involved in their oxidation. Moreover, due to the 
complex nature of biological matrices and low abundance of possible toxic conjugates, 
this technique results in poor selectivity and sensitivity. This study developed and 
optimized an analytical method based on coupling electrochemical redox reactions and 
mass spectrometry to generate, detect and identify RMs from antithyroid drugs. The 
metabolites were also compared to those that were generated using chemical oxidants and 
ii 
 
biological microsomes. Mimicry of enzymatic oxidation of the antithyroid drugs was 
carried out by electrochemically oxidizing them using a coulometric cell coupled on-line 
to electrospray ionization mass spectrometry (EC/ESI-MS). Oxidation of MMI and 
subsequent trapping with nucleophile resulted in formation of adducts with N-
acetylcysteine, revealing reactive metabolites. The most-postulated metabolite, sulfenic 
acid, had never been isolated or detected until now, using electrochemistry on-line with 
electrospray ionization. The results showed that bioactivation of MMI proceeds 
predominantly through the S-oxide and not through formation of thiyl radicals. These 
same trapping experiments were also conducted with PTU, but no conjugates were 
detected. The lack of conjugates from PTU does not preclude formation of RMs, but 
asserts radical pathway might be dominant in EC oxidation. A double mixing stopped 
flow was used to investigate the kinetics and mechanism of reaction of the MMI and the 
biologically relevant hypochlorous acid (HOCl), a product of oxidation of chloride (Cl-) 
ions by myeloperoxidase. The products from the chemical oxidations were compared to 
the electrochemically generated metabolites, some differences were apparent.  Human 
liver microsomes (HLM) were also used, to investigate oxidation of PTU. Oxidation of 
PTU, resulted in the supposedly toxic S-oxide, but this has never been isolated, save for 
speculation. A comparison of metabolites that were found with HLM to those generated 
electrochemically showed some degree of similarity. These results show that in vitro 
techniques such as chemical oxidations and electrochemistry coupled to mass 
spectrometry can be used to mimic oxidative metabolism and subsequent high throughput 
screening of reactive metabolites.  
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CHAPTER ONE 
INTRODUCTION AND RATIONALE 
Drugs undergo different phase I biotransformations such as oxidations, 
reductions, hydrolysis, hydration and condensation followed by phase II conjugation 
reactions such as glucuronidation which results in detoxification.
1,2
 Oxidative reactions 
catalyzed by cytochrome CYP450 enzymes forms the bulk of these biotransformations.
3
 
The enzymatic biotransformation of drugs and xenobiotics usually results in 
detoxification and subsequent elimination of the drug metabolites from the body.
4
  
However, in some cases, the drugs are bioactivated to toxic  reactive metabolites.
5
 
Reactive metabolites have been found to play a major role in drug-induced toxicity, 
leading to adverse drug reactions.
6
 These transient metabolites are electrophilic in nature 
and have the capacity to bind covalently and irreversibly to cellular macromolecules 
resulting in formation of  haptens.
7
  These can then induce drug adverse events such as 
direct target damage e.g., liver injury or immune mediated toxicity.
8
  
ADRs rank between 4
th
 and 6
th
 leading cause of death and results in withdrawal of 
drugs from the market.
9-11
  These adverse drug reactions can be classified as either 
idiosyncratic (unpredictable) or intrinsic; which are non-idiosyncratic (predictable), as in 
the case of liver injury due to acetaminophen overdose as they are dose dependent.
12,13
  
Utrecht defined idiosyncratic toxicities as adverse drug reactions that do not occur in 
most patients and do not involve the known pharmacological effects of a drug.
14
 Several 
drugs have been withdrawn from market or from use after reports of hepatotoxicity were 
noted .
15-18
  Some of them have been in use for years e.g., the anti-diabetic troglitazone,
19
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talcapone, trovafloxacin
20
 and the  anti-inflammatory drug (NSAID) sudoxicam
21
. The 
common feature with all these drugs was their bioactivation to reactive metabolites 
during metabolism.  
Although there has been extensive research in the field of chemical toxicology; 
reliably predicting the occurrence of idiosyncratic adverse drug reactions (IADRs) still 
remains elusive
22
. Three main hypotheses have been suggested to explain how reactive 
metabolites might induce immune-mediated idiosyncratic reactions. These are the hapten 
hypothesis, the danger hypothesis, and the pharmacological interaction (PI), as shown in 
Figure 1.1, below. The PI’s hypothesis suggests that drugs which lack hapten 
characteristics actually bind covalently and irreversibly to cell receptors resulting in an 
immune response.
23,24
   
3 
 
 
Figure 1.1 Hypothesis in etiology of drug induced liver injury. Adapted from Deng et al 
Pharmacol Rev 61:262–282, 2009
25
 
 
The current understanding of IADRs indicates that there are several 
molecular/cellular mechanisms that are not mutually exclusive and can arise from either 
direct or off-target effects either from the parent drug or its metabolites
14,25
 as shown in 
figure 1.1. Although the relationship between idiosyncratic adverse reactions and reactive 
metabolites is not well established, evidence in figure 1.1 and other sources show that 
drugs and their reactive metabolites are involved at the onset of idiosyncratic toxicities.
26-
4 
 
29
 In general, the formation of reactive metabolites in drug metabolism is considered 
unsafe.
30
  Therefore it is important to understand mechanisms by which bioactivation 
occurs for the purpose of screening and structural characterization of metabolites in order 
mitigate the risk associated with these reactive metabolites during drug design and even 
during therapy. This will go a long way in reducing attrition rates in drug development. 
1.1 Methods for characterization of reactive metabolites 
 
Toxicity of  drug candidates contributes about 21% towards failure of lead drug 
candidates during development.
31,32
 As mentioned above, the major culprits are the 
unexpected and sometimes reactive metabolites. Different methods have been employed 
in screening and characterization of reactive metabolites. Techniques using mass 
spectrometry have become the workhorse in drug development and discovery.
33
 Current 
methods to detect and identify reactive metabolites are based on indirect measurements 
by mass spectrometry.
34
 The reactive metabolites from bioactivation of drugs are 
electrophilic and sometimes radical in nature.
7
 These metabolites are short-lived, with 
half-lives of usually less than 1 minute, and are not normally detectable in plasma or 
urine,
35
 but  they can be detected as phase II conjugates.
36
 Most reactive metabolites can 
be captured by  trapping them with nucleophiles such as N-acetyl cysteine, methoxyl 
amine and GSH to form stable adducts in microsomal incubations.
37
  The trapped 
conjugates are usually analyzed using a combination of liquid chromatography and 
tandem mass spectrometry (LC/MS/MS). Other techniques such as infrared spectroscopy 
(IR) and NMR may also be used for full structural elucidation.  A slightly similar method 
of trapping and identifying the conjugates uses radiolabeled compounds such as [
35
S] 
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cysteine,  [
14
C] sodium cyanide and  [
35
S] glutathione.
38
 However, this is a low 
throughput technique and is also expensive, which makes it unsuitable during lead 
optimization.
39
 Measurement of covalent binding to liver microsomal proteins in 
presence and  absence of NADPH is another method that is used to screen for 
metabolites.
40
 
1.2 Electrochemistry/liquid chromatography/mass spectrometry (EC/LC/MS) in 
drug metabolism 
 
The conventional method of studying oxidative drug metabolism during preclinical 
experiments is through animal models (in vivo) or perfused organs in vitro.
41
  However, 
the use of animals in experiments involving scientific research and biological testing has 
raised concerns over the years among animal advocates.
42
  In view of this as well as the 
large number of drug candidates emerging and those existing, there has been a renewed 
interest in the development of complementary tools for mimicry of oxidative metabolism. 
Although it remains a challenge to extrapolate data generated from such systems to actual 
in vivo systems, these biomimetic tools offer some advantages that are not inherent in the 
conventional methods.  
Electrochemistry coupled on-line to liquid chromatograph/mass spectrometer 
(EC/LC/MS) has the potential to mimic redox metabolism. Research has shown that 
electrochemistry can be coupled to mass spectrometer in order to detect products of 
oxidation. 
43-48
 The EC/LC/MS method offers the advantage of generating and isolating 
reactive metabolites in the absence of physiological endogenous material, where usually 
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the endogenous matrix components will immediately bind to the reactive metabolites 
resulting in evasion of detection.
49-51
  Jurva and co-workers reported that reactions such 
as N-Dealkylation, S-Oxidation, P-Oxidation, alcohol oxidation and dehydrogenation that 
proceed via a mechanism initiated by single electron transfer or hydrogen abstraction are 
amenable to electrochemical oxidation.
52
 Therefore EC/LC/MS can be used to mimic 
biotransformation, synonymous to CYP450’s.  Different experimental setups can be used; 
a column may be used between the cell and the mass spectrometer, for purification if 
needed. However, this may slow the time taken by metabolites to be detected from mass 
spectrometer.  
1.3 Bioactivation of Sulfur based drugs 
 
Microsomes contain both flavin-containing monooxygenases (FMO) as well as 
CYP450’s. CYP450’s are usually involved in bioactivation of drugs, through oxidative 
metabolism
53
. They both use molecular oxygen and NADPH for the oxidation of 
substrates (S).  
  S + O2 + 2e + 2H+    SO + H2O ……………. (1) 
The bulky of oxidation process is simply insertion of oxygen on to the substrate.  Our 
research in the past has focused on investigating the mechanism of S-oxidation of 
organosulfur compounds.
54,55
  Extensive studies from our laboratory have shown that 
nearly every organosulfur compound presents a unique reactivity and no generic 
oxidation pathway can be easily derived. The sulfur atom has been implicated as a site of 
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bioactivation, resulting in formation of reactive and potentially  toxic metabolites from 
bioactivation of sulfur containing drugs.
56
  Many of the adverse reactions produced by 
penicillamine and other compounds with an active sulfhydryl group form a distinctive 
pattern when viewed as a class. Alterations in taste perception, mucocutaneous lesions, 
proteinuria due to immune-complex membranous glomerulopathy, and pemphigus are 
adverse reactions that have been encountered with all of these compounds.  Classic 
examples include the thiol, captopril, a still-used antihypertensive drug which comes with 
a black box warning and is associated with hepatotoxicity.
57-59
  It can only be used in low 
doses and after careful selection of patients to avoid idiosyncratic drug reactions and thus 
cannot be used for patients with severe hypertension.
58
  Troglitazone, a thiazolidinedione, 
developed for diabetes mellitus type 2, had to be withdrawn from market because it 
caused severe liver injury.  Thiazoles such as Sudoxicam were withdrawn in Phase III 
trials when it was already apparent that the drug was rife with IDR’s; while a closely-
related drug, Meloxicam, has not been associated with any IDR’s.  This study 
investigates the bioactivation of two sulfur based drugs, methimazole and  6-propyl-2-
thiouracil. These two drugs are used as antithyroid drugs. Bioactivation of thionamides to 
reactive intermediates have been implicated in adverse drug reactions. Thionamides 
drugs are  associated with idiosyncratic  toxicity, characterized by skin reactions, 
leucopenia, agranulocytosis, aplastic  anemia, hepatitis and cholestasis.
60
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1.4 Mechanism of action of antithyroid drugs 
 
Peroxidases oxidize iodides in the presence of H2O2 to form I
+ 
ions, which in the 
presence of  this enzyme, binds to thyroglobulin.
61
  6-propy-2-lthiouracil (PTU) and 
methimazole (MMI) block the thyroid hormone synthesis by inhibiting the thyroid 
peroxidase (TPO) or diverting oxidized iodides away from thyroglobulin.  
1.5 Significance of this research 
 
This research has the potential of being informative on the design of in vitro 
experiments, and to refine as well as reduce in vivo animal trials. This is crucial in early 
drug development and can be used to weed out unsuitable candidates for further 
development, thus reducing late stage compound failures. This technique can be adopted 
by the pharmaceutical industry as an alternative or complementary technique to existing 
screening methods. Successful isolation and synthesis of additional/novel reactive 
metabolites can enhance further studies in bioassays and toxicological studies. This will 
also add value in understanding the generation of reactive metabolites, for example, the 
long speculated sulfenic acid responsible for hepatotoxicity  in oxidation of methimazole 
was first reported as part of this work.
62
 Further development of this method can lead to 
automation and thus reduce the time required for analysis. Apart from metabolism, this 
technique has potential to be used as an analytical tool for detection and determination of 
other compounds or drug concentrations; e.g., in plasma samples, as electrochemistry is a 
sensitive technique that can be used at  very low concentrations. 
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CHAPTER TWO 
INSTRUMENTATION, MATERIALS AND METHODS 
2.1 INSTRUMENTATION 
2.1.1 Electrochemical apparatus 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Basic potentiostat circuit and a three-electrode cell, [Courtesy of Gamry 
Instruments® application notes] 
 
Figure 2.1, above shows a basic three electrode cell (sensor) that utilizes a 
potentiostat hardware, which is used to control the electrode cells for running 
electroanalytical experiments. The electrode cell is composed of a working electrode 
10 
 
(WE), whose function is to serve as a platform on which the electrochemical reaction 
takes place. The second electrode is the reference electrode (RE), its function is to 
measure any potential quantity present in WE electrode.
63
 A third electrode, the counter 
electrode (CE) completes the circuit. Its sole purpose is to conduct current into or out of 
the cell. This current has to exactly balance the current generated at the working 
electrode. Cyclic voltammetry was used in the initial phase of these experiments, to 
optimize the technique of coupling electrochemistry to mass spectrometry.  Were the 
oxidation potential of an electroactive compound in a given medium was not known, 
preliminary studies were conducted using cyclic voltammetry which gave an insight on 
the required optimum potentials. Despite the difference between cyclic voltammetry and 
the technique that was mostly used here, the electrochemical apparatus have similar 
design and same principle of operation as the cell shown above, except that the analyte 
flows through the working electrode, vide infra. The ESA Coulochem III
®
 Multi-
Electrode Detector used here is equipped with the DC Potentiostat Board as well as 
Pulse/Scan Potentiostat Board. The analogue signals were controlled by electronic 
circuits, in the logic module.
64
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2.1.2 LTQ-orbitrap Electrospray-Ionization Mass Spectrometry (ESI-MS) 
 
 
Figure 2.2. Schematic diagram of LTQ- Orbitrap Mass Spectrometry [Courtesy of 
Thermofisher Scientific Application Notes] 
 
Mass spectra of the electrochemical oxidation metabolites were acquired on a 
high-resolution (m/Δm = 30 000) Thermo Scientific LTQ-Orbitrap Discovery mass 
spectrometer (San Jose, CA) equipped with an electrospray ionization source. Figure 2.2 
shows a schematic diagram of an LTQ-orbitrap mass spectrometer. It is a hybrid 
instrument that combines the linear trap and orbitrap thus making it more robust in 
detection, identification, and characterization of samples, including biological 
complexes.
65,66
 It has high mass accuracy, high resolving power, high sensitivity and MS
n
 
capability, although tandem mass spectrometry was not utilized in these 
experiments.
67
 The instrument above uses electrospray ionization for its ion source. See 
figure 2.3 below. 
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Figure 2.3:  Schematic representation of electrospray ionization source
68
 
 
 Electrospray ionization (ESI) is a soft ionization technique used for production of 
gas phase ions, without fragmentation of the molecule being observed. Figure 2.3 shows 
an ESI process, the transfer of ionic species from solution into the gas phase by ESI 
involves three steps: (a) dispersal of a fine spray of charge droplets,  (b) solvent 
evaporation and (c) ion ejection from the highly charged droplets.
68
 The charged droplets 
generated at the exit of the electrospray tip pass down a pressure and potential gradient 
toward the linear trap analyzer, then into the C-trap where the ions are cooled and slowed 
down, then into another analyzer, the  orbitrap, and finally to the detector.
69
 The mass 
spectrum is a graphical display of the relative abundance of ion signals against the m/z 
ratios. It is a common practice that the highest signal is taken as 100% abundance and all 
the other signals are expressed as a percentage of this peak. Details of full operation of 
each component of the mass spectrometer are described elsewhere in literature.
70
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2.1.3 Coupling electrochemical apparatus to LTQ Orbitrap MS 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Schematic of EC/ESI –MS system. Coulochem III Electrochemical Detector® 
controls potential of the flow through cell.  
 
A schematic representation of EC-MS coupling is shown in Figure 2.4. ESA 
Coulometric cells 5150 and 5021A or 5130 and 5021A were interfaced to an LTQ 
Orbitrap mass spectrometer.  The potential to the cells was controlled using a potentiostat 
in the form of an ESA Colouchem III detector. This unit has a front panel with key 
controls to input and change different parameters such as potential and current output. 
The cells described above are equipped with a flow through graphite working electrode, 
solid-state palladium (Pd/H2) reference electrode and a palladium counter electrode.
64
 
GSH 
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Solutions of analytes and electrolytes were infused into the flow through cells using a 
syringe pump at different  flow rates, depending on the requirements of the experiment. 
In trapping experiments, the effluent from the cell was directed into a T-junction where it 
would be mixed with a trapping solution also pumped  from another syringe pump into 
the mass spectrometer. 
Coupling electrochemistry techniques to a mass spectrometer is not trivial and is 
not common.  Several practical aspects have not yet been fully explored. Optimum 
coupling conditions are required for EC/MS technique. Electrospray Ionization Mass 
Spectrometry is associated with high voltage at the ionization source, for example the 
spray voltage used during positive mode experiments was +4.5 kV.  This can result in 
backward electric currents flowing through the electrolyte into the cell and detector. The 
magnitude of this current can be large and dangerous resulting in electric shock to the 
operator as well as damage to the cells and detector. In order to avoid this, a ground point 
was introduced between the mass spectrometer and the electrochemical equipment. On-
line experiments coupling the cell to mass spectrometer were performed with a 
decoupling union kit that was used to ground and decouple the high voltage from the 
ESI- MS as shown in Figure 2.4. Optimum performance of the above setup was realized 
with ESI source parameters set as follows: spray voltage, 2.5 kV in negative mode and 
4.5 kV in positive mode; spray current, 1.96 (μA); sheath gas flow rate, 20 L/min; 
auxiliary gas flow rate, 0.01 L/min; capillary voltage, −16 V; capillary temperature, 300 
(°C); and tube lens, −115 V. Detection was carried out in both the negative and positive 
ionization mode (−ESI) for 4 min. The detection parameters were set up as follows: 
15 
 
Analyzer: FTMS, positive and negative polarity; mass range, normal; resolution, 30 000; 
scan type, centroid. 
 
2.1.4 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
Nuclear magnetic resonance spectrometry (NMR) spectroscopy was also used in 
structural characterization and verification of products and intermediates.  However, it 
was of little use in EC-MS experiments. Stability of reactive intermediates is dictated by 
local environment.  After lyophilizing and purifying the products for NMR analysis, there 
were changes in environment and morphology, hence intermediates were not observed in 
NMR spectra.  By their nature the intermediates are short lived and isolating them is not 
trivial. Hence we tried to do a real time analysis. NMR results obtained showed mostly 
substrate, even after oxidation, it is as expected since the S-OH bond is unstable. NMR 
experiments described above were conducted using a Bruker AMX-400 MHz Nuclear 
Magnetic Resonance (NMR) spectrometer. The atomic nucleus is a spinning charged 
particle, and it generates a magnetic field.  
 
2.1.5 Conventional UV/Vis Spectrophotometry  
 
Kinetics and reaction dynamics were carried out using spectrophotometric 
techniques. Slow reactions that occurred in more than sixty seconds were measured using 
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer system within the range 200 to 
800 nm. For these instruments, holographic grating was used as the monochromator and 
16 
 
two radiation sources, a deuterium lamp (UV) and a halogen lamp (visible range) were 
used in sequence as the polychromator light sources. The Perkin Elmer 
spectrophotometer was interfaced to a desktop computer and uses the UV WinLab 
Software for data collection and analyses. Path length of the cuvette was 1 cm. Constant 
temperature was maintained by use of a circulating water bath attached to the cell 
holders. 
 
2.1.6 Stopped Flow Spectrometry 
 
Figure 2.5. Sample Handling Unit (SHU) flow circuit diagram for SF-61DX2 Hi Tech 
Kinet Asyst Stopped flow Spectrometer. [Courtsey of Hi- Tech Scientific Operators 
Manual] 
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Rapid reactions with time scales of less than 10 seconds were measured using the 
stopped-flow technique, which can follow reactions with time scales as short as 1 
millisecond. The Hi-Tech Scientific SF61 – DX2 Double mixing stopped-flow 
spectrophotometer was used for the acquisition of absorbance data, it allows for changes 
in optical properties as a result of reactions to be monitored using UV/VIS. A stable 
Xenon Arc lamp was used as the light source. The instrument was interfaced to a desktop 
computer via a 413 kHz 16 bit A/D converter to enable the conversion of analog data to 
digital form. Small volumes of solutions are driven from high performance syringes 
through a high efficiency mixer(s). The sample handling unit (Figure 2.5) facilitates both 
the single mixing of two reagents, using only one of the drives, and double mixing of 
three reactants by a push-push mode of operation. However, experiments were conducted 
in single mixing mode. Double mixing mode enables transient species formed by mixing 
reactants in A and B to be subsequently mixed with a third reactant, C, after a delay 
period. Reactant reservoir D is reserved for the buffer and this will push the premixed 
solutions A and B (from mixer 1) to a second mixer (mixer 2) where it reacts further with 
reactant C. The resultant mixture passes through a measurement flow cell and into a 
stopping syringe where the flow is stopped. Just prior to stopping, a steady state flow is 
achieved. As the solution fills the stopping syringe, the plunger hits a block, causing the 
flow to be stopped instantaneously, and an absorbance is then recorded. 
73
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2.2 MATERIALS AND METHODS 
2.2.1 Chemicals   
 
Reagent grade methimazole, 6-propyl-2-thiouracil,(PTU) reduced glutathione, N-
acetylcysteine and methoxylamine, perchloric acid and sodium perchlorate, 
acetaminophen, reduced glutathione, acetic acid, and ammonium acetate were obtained 
from Sigma Aldrich and were used without further purification..  Ammonia, methanol 
and formic acid, ammonium acetate, acetic acid, sodium formate, acetonitrile, phosphate 
monobasic and phosphate dibasic were from Fischer Chemicals. Water  for all 
experiments were purified using a Barnstead Sybron Corp. water purification unit capable 
of producing both distilled and deionized water (Nanopure ). Solvents used for 
electrochemical oxidation and mass spectrometry were HPLC grade. Human liver 
microsomes, rat liver microsomes, NADPH regenerating system were obtained from 
Corning. 
 
2.2.2 On-line EC/ESI-MS electrochemical oxidation of Analytes 
 
Experiments were carried out in acidic, neutral and alkaline medium.  The  
analyte was dissolved in acidic medium which consisted of 20 % methanol with 80 % 20 
mM formate buffer ( pH 2.75).  For neutral medium, a combination of 20 % methanol 
with 80 % 50 mM phosphate buffer (pH 7.4) was used.  Alkaline media utilized a 20 % 
methanol with 80% 20mM ammonium  buffer solution (pH 10.2).  A 500 µL sample was 
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infused through the electrochemical cell at a flow rate of 10 µL/min before the cell was 
turned on. With the cell turned on, species generated from oxidation in each medium 
were monitored on the mass spectrum generated on-line. The potential was changed 
manually on the front panel of control module of ESA Coulochem III Electrochemical 
detector from 100 mv to 1200 mv. Each scan acquisition lasted for four minutes. The 
optimum potential was determined first before acquiring data. 
 
2.2.3 Experimental procedure for trapping experiment 
 
A 100 µM sample of analyte in suitable electrolyte-solvent system was infused 
through the electrochemical cell at a flow rate of 10 µL/minute.  A solution of containing 
the nucleophile (e.g. N acetyl cysteine) 500 µM from another syringe was then infused at 
the same rate. The effluent from both channels combined and mixed at a T-junction 
flowed into the cavity of mass spectrometer as shown in Figure 2.4. 
2.2.4 Purification and standardization of chlorite 
 
Commercially-available sodium chlorite varied in purity (78−88%), with the main 
impurities being chloride and carbonate. The sodium chlorite was recrystallized once 
from a (1:1:1) water/methanol/acetonitrile mixture to bring the assay value to 96%. These 
were stored in a desiccator in small batches of 5 g or less to avoid possible explosions.
74
 
The recrystallized chlorite was standardized iodometrically by adding excess acidified 
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potassium iodide and titrating the liberated iodine against sodium thiosulfate with freshly 
prepared starch as an indicator as described previously.
75
  Chlorine dioxide was prepared 
by the standard method of reducing sodium chlorate in a sulfuric acid/oxalic acid 
mixture.
76
 The stream was passed through a sodium carbonate solution before being 
collected in ice-cold water at 4 °C at a pH of ∼3.5. Standardization of ClO2 was also 
accomplished by iodometric techniques through the addition of excess acidified 
potassium iodide and back-titration of the liberated iodine against standard sodium 
thiosulfate. The chlorine dioxide was stored in an acidic medium in a volumetric flask 
wrapped in aluminum foil at 4 °C. Chlorine dioxide was also standardized jointly by its 
molar absorptivity coefficient (ε) of 1265 M
−1
 cm
−1
 at 360 nm on a PerkinElmer Lambda 
25S UV/vis spectrophotometer.  
 
2.2.5 Reaction Dynamics 
 
Kinetics experiments were carried out at 25 °C and at an ionic strength of 1.0 M 
(sodium perchlorate). The  ClO2 
−
/ClO2/ MMI reactions were monitored 
spectrophotometrically at λ = 360 nm, as the reactions were performed in excess chlorite 
in order to utilize formation of chlorine dioxide as an indicator of reaction progress. 
Reactions monitoring consumption of MMI were monitored at 260 nm, where MMI has 
its strongest absorption peak. Kinetics measurements were performed on a Hi-Tech 
Scientific double-mixing SF-61DX2 stopped-flow spectrophotometer. Stoichiometric 
determinations were carried out by mixing various ratios of chlorite and MMI (in an 
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acidic medium to avoid alkaline disproportionation of ClO2) in stoppered volumetric 
flasks and scanning them spectrophotometrically for the formation of ClO2 after an 
incubation of up to 2 days. Qualitative and quantitative analysis of the sulfate produced 
was performed through its precipitation as BaSO4. For reactions run under excess 
chlorite conditions, the excess oxidizing power was evaluated by the addition of excess 
acidified iodide, which was titrated against standard thiosulfate with freshly prepared 
starch as an indicator.  
 
2.2.6 Microsomal enzymatic oxidation 
 
Human liver microsomes were obtained from Corning. A well-established 
protocol for microsomal incubation (provided from Corning upon purchase of the 
microsomes) was followed with minor changes to suit the experiment and substrates 
involved. The microsomal fractions were stored at -80 
o
C and thawed immediately before 
each experiment. The following quantities were used. Initially, 713 µL of purified water, 
200 µL of 0.5 M potassium phosphate buffer pH 7.4,  50 µL NADPH regenerating 
system solution A (solution A contains NADP+ and Glucose-6-phosphate), 10 µL 
NADPH Regenerating system solution B ( Solution B contains Glucose-6-phosphate 
dehydrogenase) 2 µL substrate in solvent, making a final substrate concentration of  
10µM, were combined before adding microsomes. When combined solution A and B  
provide the regenerating system for all NADPH requiring oxidase assays.  After warming 
in  a 37
o
C water bath for five minutes, the reaction was then initiated by adding 25 
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µL(0.5 mg ) liver microsomes and then was mixed and   returned  to a  37 
o
C water bath. 
After 60 minutes a 100 µL aliquot from the incubation was withdrawn and the reaction 
was terminated by adding 100 µL acetonitrile.  This was then mixed and placed on wet 
ice followed by centrifuging at 10,000 Xg  for three minutes. The supernatant from the 
protein pellets was withdrawn for analysis using  LC/MS. Incubations without NADPH 
and microsomes were used as controls, to ensure that  formation of metabolites was 
dependent on HLMs and NADPH. 
 
2.2.7 LC-MS analysis. 
 
The metabolites produced by incubation of PTU, were collected and analyzed by 
LC-MS. The separation of the metabolites was achieved using a reverse phase Zorbax 
Eclipse Plus 3.5µm, C8 column. Colum dimensions were as follows: 100 mm x 2.1 I.D. 
The flow rate was set at 200µL/min and the injection volume was 20 µL/min. The 
gradient separation was performed by two solvents.  Mobile phase A: 0.1 % acetic acid in 
water and mobile phase B: 0.1 % acetic acid in methanol.  The applied gradient profile 
was 10 % B for 5 minutes, followed by 30 % for another 5 minutes, and then 50 : 50 for 
two minutes and finally 90%  B for the last six minutes. The column was operated at 
35
o
C. The MS based detection was carried out it positive ion mode using both FTMS  
and ITMS detection 
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2.2.8 Structural elucidation, mass accuracy and theoretical m/z calculations 
 
High resolution mass spectrometry allowed calculation of mass accuracy with a 
relative error of less than 4 ppm, providing unequivocal identification of metabolites. 
Hence, the exact nature of modification of the metabolites was elucidated, eliminating 
possibilities of false positives, which results during identification of metabolites. High 
resolution MS data-processing and calculation of elemental compositions were carried 
out using the Qual browser of Xcalibur SR2 Thermo Fisher Scientific. Xcalibur™ 
software was used to arrive at the proposed structures.  For example, the elemental 
composition calculator in Xcalibur™ returns 10 possible elemental compositions within 
+/- 100 ppm for the measured mass at m/z 129.01143 (See figure 2.6) giving all plausible 
chemical compositions hence structures for that peak, within that mass tolerance.  When 
the mass tolerance was within +/- 4 ppm (high accuracy); only one composition 
combination was possible, figure 2.7.  In addition, even electron ions are assumed since 
electrospray ionization (ESI) was used for ion generation. Simulation of the proposed 
elemental compositions under the measured spectrum was also used in mining possible 
chemical formula for the major ions
77
 (Figure 2.8). ChemBioDraw
TM
 was used in 
obtaining exact masses for the proposed structures and calculation of mass accuracy from 
exact versus observed masses, with five decimal places.  Mass tolerance for reported 
structures was within +/- 4 ppm, giving high mass accuracy and an unambiguous 
assignment of the peaks.
78
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Figure 2.6: Qual BrowserTM showing simulation for elemental composition using 
Xcalibur™,  calculator, showing 10 possible composition at low accuracy of +/- 100 
ppm.  
  
25 
 
 
 
Figure 2.7: Qual Browser
TM
 showing simulation for elemental composition using 
Xcalibur™,  calculator, showing only one  possible composition at high mass accuracy 
of +/- 4  ppm.  
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Figure 2.8: Simulation of the proposed elemental compositions under the measured 
spectrum confirming chemical formula for the major ions. 
 
By exploiting the capability of LTQ-Orbitrap
TM
 and the Qual Browser
TM
 software 
which gives exact mass measurement at high resolution,
79
 it was able to identify 
modifications on analyses. These software allows identifications of small molecules, even 
in complex endogenous matrix with microsomes, this has become standard practice in 
drug development.
80
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2.3 OPTIMIZATION OF PARAMETERS 
2.3.1 Optimization of electrochemical methods 
 
The most important part of developing this technique was to optimize it with drug 
whose behavior is well established. In the electrochemical cell used in these studies, the 
conversion rate of analytes to metabolites was affected by flow rate, pH of the electrolyte, 
and nature of the analyte as well as the potential applied to the electrochemical cell
48
. 
APAP is oxidized into well-known hepatotoxic (n-acetyl-p-benzoquinoimine) NAPQI 
which forms conjugates with thiols such as GSH and N-acetyl-l cysteine
81
. 
Electrochemical properties of acetaminophen (APAP) are well characterized and 
documented in literature,  hence APAP was chosen as the test compound in order to 
optimize the method.
48,82
 Getek et al, successfully coupled the coulometric cell to a mass 
spectrometer and were able to detect APAP conjugates with glutathione and cysteine
81
.  
Formation of its reactive metabolites and their subsequent conjugation with glutathione is 
also well established. A number of studies using cyclic voltammetry reported that APAP 
is oxidized to the reactive metabolite N acetyl-p- benzoquinone imine (NAPQI).
83,84
 
Cyclic voltammetry was used initially to determine oxidative potential of APAP.  
Potentials between 450 mV- 650 mV with respect to Pd/H2 electrode, were established  to 
be optimum oxidation  potential for  acetaminophen. Different pH conditions, solvents 
and potentials were tested as described in literature. The parameters described in 
literature were modified in order to suit the available equipment. For cyclic voltammetry 
the optimum pH was found to be 6.4.   
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2.3.2 Sample preparation and delivery 
 
A 10 µM solution of APAP solution in 20 mM ammonium acetate, pH 6.4 in 20 
% aqueous methanol, was infused into the Dionex synthesis cell model 5051 using a  
syringe pump at flow rate of 10 µL/min. The effluent from the cell was directed into a T-
junction where it was mixed with a solution of 50 µM GSH, also pumped at a rate of 10 
µL/min from another syringe pump into the mass spectrometer. The flow-through 
coulometric cells used here were associated with high back-pressure and clogging, 
resulting in leakages in the system and breaking of the gas tight syringes, stalling 
experiments. Instead of using a micron filter that was connected to cell, to prevent fouling 
and clogging of electrodes, the solutions were filtered off-line before being introduced to 
the cell. Using the cell without the micron filter reduces back-pressure therefore leakages.  
Plastic syringes were used versus gas tight glass syringes. Although using gas tight, glass 
syringes sounds convenient, under compressive stress glass syringes were easily breaking 
as opposed to plastic syringes that would yield and bend. Thus high flow rates above 
50µL/min resulted in high back pressure, subsequent breaking and leaking. These 
parameters were optimized during this phase.  Optimum flow rates were found to lie 
below 40 µL/min. The syringe pump on the Orbitrap could only be used with flow rate of 
10 µL/min thus reducing the pressure. Despite the limitation imposed by flow injection, 
lower flow rates resulted in higher conversion of analytes into metabolites, due to the 
extended residence time in the cell. Effect of residence and ageing times of analytes in 
the cell were also determined during optimization stage. 
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2.3.3 Results  and discussion from optimization 
 
Figure 2.9 shows the mass spectrum obtained from oxidation of APAP at 650 mV 
vs Pd/H2  solid state reference electrode  and its reaction with GSH. The most dominant 
peaks at m/z 152 is due to acetaminophen [M+H
+
] and m/z 308 is GSH [M+H
+
]. The next 
largest peak at m/z 615 was generated by GSH disulfide (GSSG). Shayani-Jam and co-
workers suggested that (N-acetyl-p-benzoquinone imine) NAPQI has a catalytic role in 
which it reacts with GSH rather than in formation of the APAP-GSH adduct as reported 
in previous publications, thus the process mimic phase I and phase II drug 
metabolism.
48,81
 They proposed that this reaction will result in oxidation of GSH to  
glutathione disulfide (GSSG) while reducing  NAPQI to APAP again, without formation 
of the adducts as shown in Figure 2.10  implying  the adduct is not the major product. 
This suggestion appears to agree with the low yield of adduct that was experimentally 
observed during the electrochemical oxidation of APAP.  
 
 
 
  
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: ESI (+) mass spectrum of APAP and GSH mixture, after APAP oxidation at 
650mv vs Pd/H2. 
 
Interestingly, the mass spectrum obtained, resulting from coupling the 
electrochemical cell to a high resolution and high mass accuracy orbitrap had both adduct 
and GSSG dimer, albeit in low concentrations. This shows that these two methods are 
synergistic and complementary to each other. It is important to note that the GSH was not 
incubated with analyte that was passed through the cell. If it was passed through the cell 
it would have been oxidized  to give its GSSG disulfide.
48
 The disulfide was instead 
oxidized by NAPQI, and not by electrochemical oxidation.  
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Figure 2.10 Cyclic voltammetry, catalytic oxidation of GSH to GSSG and subsequent 
reduction of NAPQI to APAP.
82
 
 
It turns out that reactive metabolites are not usually produced in large quantities; 
however their binding to macro cellular molecules has large impact in ADRs. These 
results clearly show that in addition to the GSSG, there is formation of APAP-GSH, 
[M+GSH+H
+
] adduct shown with m/z 457. Due to the nature of their reactivity and low 
concentrations, these electrophilic metabolites are difficult to detect and are often 
suppressed during detection of endogenous materials. The LTQ Orbitrap has an 
advantage of high resolution and has high mass accuracy detection allowing assessment 
of the exact nature of the modification that took place on the parent compound. The 
conjugate and disulfide were identified based on their accurate mass data, with deviations 
of less than 4 ppm. Due to this high sensitivity; low metabolite concentrations can be 
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detected using  EC coupled to high resolution MS. Physiological processes are such that, 
the reactive metabolites are quickly detoxified; thus they will only be available in very 
small quantities and therefore will be difficult to detect. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1: Reaction scheme for the oxidation of APAP in the presence of GSH.
48
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A well-known established electrochemical reaction pathway for oxidation of 
APAP is a 2 electron oxidation process  that is initiated by the loss of  single electron and 
proton, resulting in formation of a radical,
48,81
 as shown in Scheme 2.1 above. This will 
be followed by another electron and proton loss to give the reactive NAPQI. In the 
presence of thiol-containing molecules such as glutathione or n-acetyl-cysteine, it will 
form adducts such as the APAP-GSH adduct appearing at m/z = 457. In vivo, APAP is 
metabolized and excreted as the nontoxic conjugates of the phase II glucuronidation 
reaction. However, during an overdose it saturates all the detoxification conjugation 
pathways and depletes intracellular reduced glutathione (GSH), hence the reactive 
metabolites will  instead react with cellular proteins binding covalently and irreversibly 
(haptenation) resulting in cellular necrosis or subsequent liver-induced injury. 
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CHAPTER THREE 
Electrochemistry-Coupled to Mass Spectrometry in Oxidation of Methimazole:  
3.1 Introduction 
 
Methimazole, an antithyroid drug used in the treatment of hyperthyroidism, has 
been associated with idiosyncratic  toxicity, characterized by skin reactions, leucopenia, 
agranulocytosis, aplastic  anemia, hepatitis and cholestasis.
85,86
 The relationship between 
idiosyncratic adverse reactions and reactive metabolites is not well established.   There is  
circumstantial evidence, however, that reactive metabolites generated during oxidation of 
methimazole are involved in the onset of idiosyncratic adverse reactions associated with 
MMI.
87,88
  We set out to investigate formation of any unexpected or reactive 
intermediates/ metabolites from MMI. These metabolites are electrophilic in nature, thus 
reactive, and have the capacity to bind to nucleophilic cellular macromolecules which can 
then elicit an immune response.  A range of metabolites have been suggested from 
biological oxidation of MMI. MMI metabolism is thought to occur through a P450-
mediated process resulting in ring scission, with further S-oxidation mediated through 
FMO to produce the tandem of  sulfenic and sulfinic acids.
89
 However, some sources 
reported that FMO sequentially monooxygenates  intact methimazole to produce unstable  
methimazole sulfenic  and sulfinic acids without ring scission.
90
  
The objective of this study was to use electrochemistry and mass-spectrometry to 
mimic oxidative metabolism in order to generate and characterize intermediates and 
products using electrospray ionization.   Various electrochemical methods using modified 
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electrodes to enhance catalytic oxidation of MMI have been developed and used for the 
determination of MMI at sub-micromolar  detection limits using cyclic voltammetry.
91-93
 
While most of these studies were focusing on detection and determination of MMI using 
electrochemical techniques, our study is designed to explore metabolic fate of MMI. 
Members of the cytochromes P450 class (CYP450) of enzymes are responsible for the 
majority of phase I biotransformations leading to reactive electrophilic intermediates.
94
 
The chemical reactivity of electrophilic metabolites usually prevents their detection in 
vivo since, by definition, they are short-lived and likely to undergo one or more structural 
modifications to form more stable final products. Electrochemical oxidation of thiol  
compounds such  MMI  is complicated by large anodic over potential and poor 
voltammetric signals. In the coulometric cell used in this study, the eluent flows through 
the electrodes rather than by the electrodes as in convectional cells.  This maximizes the 
contact of the electro-active compound in solution with the electrode surface, ensuring 
that diffusion and convection controlled process do not  limit the electrochemical 
oxidation of the compound.
95
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3.2 RESULTS AND DISCUSSION 
3.2.1 Electrochemical Oxidation in basic medium 
 
Technical limitations with respect to the spectrometer cavity could not allow for a 
faster flow rate of more than 10 μL per minute.  Figure 3.1 shows the on-line negative 
mode ESI spectrum obtained, at  5 μL per minute.  The residence time of the substrate in 
the oxidation chamber was generally long enough for full oxidation of MMI to its full 
oxidation products of the sulfonic acid at 600 mV.  The reaction could be slowed down 
by running the oxidation in basic environments.  
 
Figure 3.1:  On-line negative mode ESI-MS analysis of methimazole oxidized in 
ammonium buffer. MMI was infused at 5 µL/minute.  At this low flow rate the substrate 
has sufficient residence time in the cell allowing complete oxidation to sulfonic acid.  
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This spectrum shows a strong peak of the sulfonic acid at m/z =161.003 and 
another for the unoxidized substrate, MMI at m/z = 113.01.  In-between, there are smaller 
peaks at m/z = 129.01 and 145.01.  These ramp to the sulfonic acid, m/z = 161.003 by 
jumps of 16 amu’s signifying these are putative the sulfenic  (or S-oxide) and sulfinic 
acids (the dioxide).  The relative abundances of the peaks indicate that the sulfenic and 
sulfinic acid derivatives are relatively unstable.  The rate determining step for the 
oxidation of MMI is the formation of the S-oxide.   
 
 
 
      
     
 
 
 
 
Figure 3.2: Putative metabolites from oxidation of MMI 
 
(c) Dimer 
 
(a) Methimazole S-oxide 
 
(b) Methimazole Sulfinic Acid 
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Subsequent oxidation (after the first 2-electron oxidation) of the S-oxide is facile, 
hence the relative low abundance of these metabolites.  Structures of the S-oxide and 
sulfinic acid metabolites are shown in Figures 3.2 a and b, respectively.  
 
Figure 3.3: Positive mode. On-line ESI spectrum acquired in basic medium.  This 
spectrum shows strong peaks for the dimer (m/z = 114.025, not labeled), the sulfenic 
acid, and the sulfonic acid.  The sulfinic acid is not observed under these conditions. 
 
Figure 3.3 shows spectra derived from on-line spectra in the positive mode.  As 
expected, the substrate now shows up at m/z = 115.03.  There is, surprisingly, a very 
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strong peak for the S-oxide at 129.01.   There is virtually no evidence for the sulfinic 
acid.  The major metabolite, before full oxidation to the sulfonic acid, is the doubly 
charged dimer, at m/z = 114.025 (Figure 3.2c).  A slow oxidation rate will allow the 
electrophilic S-oxide to react with the thiol substrate in a condensation-type reaction to 
produce the dimer.  Dimeric disulfides are not as reactive as the original thiols, and thus 
they accumulate.  Their further oxidation rates back through the sulfenic acid are 
relatively slower. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Negative mode.  Off-line synthesis and analysis of MMI oxidation products. 
The products were identified with a mass accuracy of 3.93 ppm and 3.43 ppm, absolute 
values, for the methimazole sulfinic acid and Methimazole sulfonic acid respectively. 
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Figure 3.4 shows the batch off-line experimental spectra.  Incubation period was 
long enough for the near-full completion of the reaction.  Since this is a batch 
environment, with no outflow of unreacted metabolites, facile reactions were able to react 
to completion.  In contrast, negligible amounts of S-oxide are observed; the major 
metabolite is the dioxide, methimazole sulfinic acid.  Since the batch environment is 
constantly in an oxidizing environment, the highly labile sulfenic acid is not observed. 
3.2.2 Electrochemical oxidation in acidic media and neutral medium. 
 
 
Figure  3.5.  Off-line Positive mode. ESI spectrum showing the oxides of Methimazole at 
pH 6.75   
115 120 125 130 135 140 145 150 155 160 165 170 175 180
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
146.03815
129.01143
115.03215
161.03781
148.03378
135.10125131.00718 168.02011116.10665
114.09101 177.05461162.03301124.09646 151.09623 158.15377 171.14910143.10642136.08847
127.07506
132.10153
41 
 
The positive mode results of the batch process are shown in Figure 3.5.  Basic 
environments destabilize electrophilic intermediates. However acidic and  slightly acidic 
environments stabilize them.  Thus, in Figure 3.5, the S-oxide is observed, as well as the 
sulfinic acid. The scale excludes the dimer. The Methimazole dimer was the predominant 
product in acidic medium Figure 3.8  page 47, structure M4).  Figure 3.6 shows strong 
peaks for the singly charged dimer at m/z = 227.04 and the doubly charged species at m/z 
= 114.03. 
 
Figure 3.6. Positive mode ESI in acidic medium. 
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3.2.3 Choice of supporting electrolyte and effect of pH 
 
Larger currents were attained in phosphate and in ammonium buffers. The same 
species obtained at pH 7.4 in phosphate were also obtained in more alkaline media of pH 
10.2.  Phosphate buffer, however, was not used for subsequent experiments.  This was 
because phosphate buffers are non-volatile and can clog the MS inlet capillary, hence 
ammonium buffer was chosen as the suitable supporting electrolyte in subsequent 
experiments.  
 
 3.2.4. Assessment of stability, reactivity of metabolites and off-line synthesis 
 
In order to perform off-line synthesis of intermediates, stability of the 
electrochemically generated species were monitored over a period of 30 h. To collect 
samples off-line, samples were infused at 40 µL/min, with potential maintained at 600 
mV. The samples were then collected in vials with one batch kept at room temperature 
and the other batch kept at -20
o
C.  Samples were analyzed by ESI-MS.  Relative 
abundances of the intermediates at m/z 129 and 146 decreased significantly after 26 h. for 
both the samples that were kept frozen at -20 
o
C and those maintained at room 
temperature. There was a 75 % decrease in abundance of these intermediates over this 
time duration.  In addition, stability of MMI was also monitored and was found to be 
stable for prolonged periods in solution.  
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S-oxidation reactions in vitro had revealed that reactive intermediates are 
produced during oxidation of MMI and these can be eliminated by addition of 
nucleophiles such as glutathione to the reaction mixture.
89
 In order to check reactivity of 
the intermediate species, samples were also incubated with a select set of nucleophiles. 
Conjugates were observed when the samples were incubated with N-acetylcysteine. 
Methoxylamine and glutathione, however did not form conjugates with MMI metabolites. 
 
3.2.5 Experimental results derived from nucleophilic trapping. 
 
Figure 3.7 shows the ESI spectrum derived from the use of N-acetylcysteine 
(NAC) as the trap.  One strong peak is observed, of a 1:1 adduct of NAC with MMI.  The 
experimental setup involved flowing NAC through a T-junction into the flow going into 
the spectrometer cavity (see Figure 2.4 schematic diagram)  
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Figure 3.7 MMI   metabolite conjugate with  N-acetyl cysteine.  There is one dominant 
adduct 1:1 adduct of the N-acetylcysteine and MMI.  There is a small peak for the S-
oxide and an even smaller peak for the dioxide. 
 
NAC was not electrochemically oxidized.  It combined with the effluent from the 
electrochemical cell as a reducing thiol.  It reacts strongly with any electrophilic species 
from the electrochemical cell.  The absence of symmetric disulfides is important: it 
means no radicals are involved in this mechanism.  The only electrophile present in the 
electrochemical oxidation cell is the S-oxide. The decrease in abundance of metabolite 
and formation of the conjugate strongly indicates that it is the reactive metabolite. The 
sulfinic and sulfonic acids are not strong electrophiles.  Figure 3.7 thus shows that the 
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sulfenic acid is very stable in the oxidizing environment but is quickly and quantitatively 
deactivated in a reducing environment such as in the presence of NAC.   This (reducing 
environment) is the expected medium in the physiological environment. The maintenance 
of an oxidizing environment in the electrochemical environment has allowed for the 
observation of those highly electrophilic intermediates that would otherwise have been 
quenched by the reducing physiological environment  
 
  
46 
 
 
List of structures 
 
 
 
 
 
 
 
 
 
 
  
3-methylimidazolidine-
2,4-dione ( M3) Methimazole S-oxide  ( M1) 
1-methyl-1H-imidazole-2-sulfinate 
(M5) 
3-methyl-2-thioxoimidazolidin-
4-one (M2)        
bis(1-methylimidazol-2-
yl)disulfide (M4) 
1-methyl-2,3-dihydro-1H- 
imidazole-2-thiolate (S3) 
1-methyl-1H-
imidazole-2-
sulfonate (M6) 
Methimazole (1-methyl-
3H-imidazole-2-thione) 
(S1) 
1-methyl-1H-
imidazole-2-thiol 
(S2) 
1-methyl-2-
(methylthio)-2,3-
dihydro-1H-imidazole 
(M7) 
1-methyl-2,3-dihydro-1H- 
Imidazole (M8) 
 4-methyl-6-oxa-2,4-
diazabicyclo[3.1.0] 
hexa-1(5),2-diene-3-thiol  
(M9) 
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Figure 3.8  List of metabolite from MMI Those labeled with a prefix of ‘S’ indicate 
different forms of the substrate, methimazole, and those with ‘M’ indicate metabolites, 
either observed in this study or in previous studies. 
 
  
N-methylthiourea 
(M11) 
Methylthiourea  
sulfenic acid 
(M12) 
N-methylthiourea 
 sulfonic acid 
(M13) 
2-mercapto-1-
methyl- 
1H-imidazole-
4,5-diol (M10) 
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3.2.6 NMR experiments 
 
 
Figure 3.9:  NMR spectra of the oxidized MMI products, the NMR shows the ring intact. 
 
NMR experiments were carried out on the products/intermediates. However, 
stability of such intermediates is dictated by local environment, after lyophilizing and 
purifying the products for NMR analysis, there were changes in environment and 
morphology, hence no intermediates were be observed. NMR results obtained showed 
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mostly substrate see figure 3.8 above, even after oxidation, it is as expected because the 
S-OH bond is unstable. 
3.2.7 Mechanism. 
 
All the data derived from electrochemical oxidations suggests a very strong case 
for a viable S-oxide.   This has been, previously, an elusive metabolite. Very strong and 
stable peaks have been observed in Figures 3.3 and 3.5.  Figure 3.6, though not showing a 
strong sulfenic acid peak, does show a peak for the dimer.  This dimer is derived from a 
sulfenic acid (vide supra).  
The oxidation pathway has a direct correlation with the physiological effects of 
MMI.  The standard accepted oxidation pathway of sulfur-based drugs is through S-
oxygenation, though the mechanism of this S-oxygenation differs with specific 
compounds based on the environment of the sulfur group.  All β-amino sulfur compounds 
are oxidized in vivo and in vitro to as far as the sulfonic acid without cleavage of the C – 
S bond.  Thus most biologically active molecules such as cysteine, glutathione, and 
cysteamine show this distinct oxidation pathway.
96-98
  In the presence of excess oxidant, 
the stoichiometry of the reaction was found to be strictly 1:3; with formation of the 
sulfonic acid and very little detectable sulfate by BaSO4 precipitation: 
 3Br2  +  RSH  +  3H2O   →   RSO3H  (Structure M3)  +  6H
+
  +  6Br
- 
        R3.1 
Most deleterious effects of bioactive compounds are ascribed to the reactive 
metabolites produced during the first pass metabolism
99
.  By nature of the physiological 
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environment, such reactive metabolites are never observed.  The first set of experiments 
carried out to detect possible reactive intermediates of MMI involved its reaction with 
aqueous bromine.  This is a ‘clean’ and strong oxidant that oxidizes in 2 one-electron 
steps to produce only Br
-
 as its reduced product: 
  ½Br2 (aq) + e-     Br-  E
o
/ V = 1.09 
  This affords the determination of the possible metabolites without interference 
from the oxidant.  A 1:1 mixture of MMI and aqueous bromine imparts a 2-electron 
oxidation which should limit oxidation of MMI to the sulfenic acid.  If the sulfenic acid is 
stable enough, it should be observed in the ESI spectrum.  Figure 3.9 shows a spectrum 
of a 1:1 mixture of MMI and aqueous bromine.  Even though the spectrum shows the 
sulfinic and sulfonic acids; the major metabolite is surprisingly, the S-oxide (Figure 3.2a, 
Structure M1).  In the absence of the reducing physiological environment, this highly 
unstable, electrophilic S-oxide can be stabilized.  Unstable S-oxides are known to 
disproportionate or to form thiosulfinates.  They are also expected to react with the 
nucleophilic remaining thiol to produce a dimer: 
  RSOH  +  RSH  →  RSSR  +  H2O     R3.2 
Under insufficient oxidant equivalents, the substrate will partition into its most stable 
intermediates at those conditions.   Spectrum in Figure 3.9 shows that the sulfinic acid, as 
expected, is not as stable as the sulfonic acid, which is the final oxidation product.  This 
spectrum was taken after complete consumption of bromine and before full 
rearrangement of the sulfur compounds as evidenced by the coexistence of the S-oxide 
and the thiol.  The spectrum obtained in Figure 3.9 was derived from unbuffered  
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solutions.  pH of the reaction solution decreased due to formation of H
+
 according to the 
reaction stoichiometry.  Thus the m/z peak at 116.99 can be ascribed to the substrate, and 
the 115.03 to the dimer.  After long incubation periods the substrate peak disappears 
completely, with a concomitant increase in the dimeric species and other unidentifiable 
thiosulfinates.  The sulfonic and sulfinic acids still show up at the expected m/z values 
because of their acidity, and thus unlikely to be further protonated despite the highly  
acidic product environment. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: ESI spectrum of oxidation of methimazole using bromine in a 1:1 mixture 
ratio. As expected, the sulfenic acid is the major metabolite in these conditions of excess 
reductant. 
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3.2.8 Proposed mechanism for electrochemical oxidation of methimazole 
 
Our experimental results can now allow us to suggest a plausible mechanism of 
electrochemical oxidation of MMI.  This is shown in Scheme 3.1.  Electrochemical 
oxidation of sulfur-based drugs is complicated by the fact that sulfur centers generally 
oxidize via 2-electron jumps, while electrochemical abstractions generally involve a 
single electron transfer at a time.  Starting with the thiol center would produce a sulfur-
based thiyl-type radical on abstraction of the first electron.  This would immediately 
precipitate a cascade of free radical reactions with a strong formation of the dimeric 
disulfide.  Our results thus lead us to the conclusion that the abstraction of the first 
electron results in the formation of a positive charge delocalized mostly over the C-N-C 
network and not a sulfur-based radical.  Zwitterionic forms of thioureido oxo-acids have 
similarly been described.
100
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Scheme 3.1: Reaction scheme for the oxidation of MMI and subsequent formation of 
sulfenic acid 
 
Scheme 3.2 below summarizes different fate of sulfenic acid. Depending on the 
environment, the sulfenic acid will react to give stable states. The reaction of sulfenic 
acid with nucleophiles such as n-acetyl cysteine may be advantageous in the 
physiological environment, as this is a detoxification pathway.  Other pathways also leads 
to less reactive metabolites. 
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Scheme 3.2: Summary of sulfenic acid 
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3.2.9 Comparison with biological metabolism 
 
Since MMI is a well-tolerated drug for hyperthyroidism, its in vitro  and in vivo  
metabolism has been extensively studied.   Human, rat and pig microsomal incubations 
with MMI have concluded that the major activation of MMI is performed by FMO’s 
rather than CYP450’s.   Presence of FMO’s however, seemed to deactivate CYP-based 
bioactivations, and it has since been established that MMI is a competitive inhibitor of 
FMO’s.
101,102
  Isolation of the effect of CYP450’s can be determined by heating, which 
deactivates FMO’s or addition of N-octylamine, which inhibits FMO bioactivations.   
The variety of metabolites obtained which involved ring cleavage to obtain methyl 
thiourea and its oxo-acids (structures  M11 – 13 in  Figure 3.8) can be attributed to 
CYP450-mediated bioactivations.   This can be justified through the initial epoxidation of 
MMI (structure M9) whose subsequent hydrolysis product of a 1,2 dihydroxy moiety can 
easily cleave the C-C bond by even the mildest oxidants.   Thus one expects a wide 
variety of possible metabolism products when microsomal oxidations are utilized to 
metabolize MMI.  The major pathway of microsomal bioactivation of MMI involves S-
oxygenation, with the sulfinic acid (structure M2) as the major metabolite.  While the 
sulfenic acid has been postulated (structure M1), microsomal incubations have never 
been able to isolate it; even though formation of M2 has to pass through M1.  Our study 
has been able to isolate this formerly postulated metabolite.  The deactivation of 
CYP450’s is clearly related to formation of a highly reactive electrophilic metabolite of 
MMI derived from FMO’s.  This has been observed with the oxidation of a novel kinase 
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inhibitor, TG100435.
103,104
  Its bioactivation by FMO’s gives an S-oxygenated S-oxide, 
TG100855, which not only deactivates CYP450’s but is also reduced back to TG100435 
during the deactivation. Thus the products, kinetics and dynamics of microsomal 
bioactivations are expected to be complex.  Our electrochemical oxidations simplify this 
process.  This makes evaluation of physiological effects, especially toxicities, easier to 
determine. 
3.4 Conclusion 
 
We have demonstrated that electrochemistry coupled to mass spectrometer can 
mimic oxidative metabolism of MMI, the mechanism initiated by  single e- transfer 
process coupled to proton (H
+
) abstraction.  The absence of complex endogenous 
material enhanced detection of an S-oxide in oxidation of MMI, this intermediate 
metabolite has been speculated before, but has never been isolated. The elusive sulfenic 
acid was captured as a conjugate with n-acetyl cysteine. Bioactivation of MMI and 
related molecules, to reactive metabolites has a direct physiological implication in 
toxicity of thionamides.   
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CHAPTER FOUR 
Kinetics and Mechanism of Oxidation of Methimazole by Chlorite in Slightly Acidic 
Media 
4.1 Introduction 
 
As indicated above, thionamides drugs, methimazole (1-methyl-3H-imidazole) 
MMI and 6 -propyl- 2-thiouracil (PTU) are two important antithyroid drugs used in 
treatment of hyperthyroidism and thyrotoxicosis.
105,106
  After administration, the drugs 
are concentrated in the thyroid gland.
107
 Hypochlorous acid (HOCI) is the most powerful 
oxidant produced by human neutrophils.  Peroxidases including thyroid peroxidase have 
been shown to contribute to oxidation of  MMI, to a range of products.
108
  Model in vitro 
studies, using myeloperoxidase (MPO) in H2O2/Cl- system, show that hypohalous acids  
are some of potent oxidants generated during catalytic oxidation of H2O2 in presence of 
Cl- or Br-.
109
 Ironically MMI is an antioxidant that scavenges reactive species, and  can 
be oxidized to potentially reactive intermediates, such as its sulfenic acid.  
A number  of  toxicological and metabolic studies have been conducted in an 
attempt  to  identify possible reactive intermediates associated with the antithyroid 
drugs.
110
 Whereas there is a general consensus on the ultimate products of oxidation of 
MMI, as sulfate and N –methyl-imidazole,
111
 there has not been a clear identification of 
possible intermediates. Other metabolites suggested from previous research include   S-
methyl imidazole,  1 methyl-2-thiohydantoic acid, methylhadantoin and 
methylthiourea.
112
 However, lack of toxic profiles by  most of these metabolites could not 
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explain the trend in observed adverse reactions  associated with MMI. Here a system that 
employs potent oxidants hypohalous acids;  HClO and HBrO  which were generated  in 
situ were used to study the rapid kinetics and mechanism of reaction of MMI oxidation.  
With mild oxidants such as  bromine,  a stable S-oxide was observed. However, in 
acidified chlorite the reaction was very fast and the resulting in the unstable intermediate 
that was short lived and was not observed in ESI.  
4.2 Results and discussion 
 
 
Figure 4.1. Spectral scans showing (a) [MMI] = 1.00 X10
-5
 M, (b) ClO2 = 1.70 x10
-4
 M 
and (c) product of reaction [MMI] = 3.00 x 10
-4
, [ClO2
-
] = 3.00x 10
-3
 and [HClO4] = 
1.00 X 10
-1
 M 
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4.2.1 Stoichiometry.  
 
 
Stoichiometric determinations utilized two complementary techniques: 
spectrophotometric and titrimetric.  The titrimetric techniques were more accurate as they 
relied on a several readings to derive a single stoichiometry.  Figure 4.2 shows a 
titrimetric analysis of residual oxidizing power.  For the whole data set shown, MMI 
concentrations were fixed at 1.00 mM.  Iodometric titrations gave the expected linear plot 
which extrapolated to 2.0 mM chlorite concentrations, showing complete consumption of 
1.0 mM MMI.  Each chlorite molecule gains 4 electrons to attain the Cl
-
 state.  This 
suggests that the only oxidation on the MMI molecule occurs on the sulfur center which 
is oxidized from -2 to +6.  Tests with barium chloride showed an almost quantitative 
formation of sulfate as expected from MMI.   
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Figure 4.2. Iodometric titration to determine stoichiometry. Fixed [MMI] = 1.00 x10
-3
 M 
, [H
+
] = 0.20 M, and varied [ClO
-2
] from 3.00 x 10
-3
 M to 8.00 x10
-3
 M, X intercept = 
0.002033  This suggests an oxidant to reductant stoichiometric ratio of 2:1 
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Despite the observed clean 2:1 stoichiometry, we could not experimentally 
determine the organic residue. However, the residue did not seem to involve any further 
oxidation, only hydrolysis and/or ring-opening.   ESI spectra of the reaction were 
acquired in solution using slightly less than stoichiometric amounts of oxidant. Figure 4.3 
shows an ESI spectrum in the positive mode.  It shows, predominantly, the dimeric 
species at m/z = 227.04313 and the N-methylimidazole at m/z = 83.0604.   N-
methylimidazole would be the expected organic residue if the sulfur atom is oxidized to 
sulfate with a concomitant cleavage of the C-S bond.  It would appear N-methylimidazole 
rapidly decomposes by hydrolysis to smaller fragments after ring opening.  
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Figure 4.3: ESI spectrum in the positive mode before reaction proceeds to completion 
showing the predominant peak of the substrate at m/z = 115.03242.   Two peaks for the 
dimeric species are observed, one at m/z = 227.04313.  The doubly-charged dimeric 
species is observed as the peak just below that of the substrate.  The N-methylimidazole 
species is at m/z = 83.06402. 
Figure 4.4 shows the ESI spectrum of chlorite and MMI with slightly less chlorite 
than that needed for full oxidation of MMI.  As expected, there is a predominant peak for 
sulfate, captured as the bisulfate at m/z = 96.96032.  There is a large peak for the sulfonic 
acid of MMI at m/z = 161.00252.  A further 2-electron oxidation of this sulfonic acid will 
give sulfate and N-methylimidazole.  There is a very tiny peak for the sulfenic acid at 
129.01273, but, surprisingly, there is no sulfinic acid, which is supposed to be more 
stable than the sulfenic acid.   Another stoichiometric determination was attempted for 
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the chlorine dioxide – methimazole reaction.  From the radical nature of chlorine dioxide, 
the stoichiometry could not be determined with certainty. From electron balance alone, 
we were expecting an 8:5 ratio, oxidant to reductant, but this was never obtained.  We 
can, however, write the following general equation for the oxidation of MMI by chlorite:  
MMI  + 2ClO2
-
  + 2H2O  →  MMI-Oxidation products  + 2 Cl
-
  +  SO4
2-
  +  4H
+  
 (R4.1) 
 
 
Figure 4.4: ESI spectrum in the negative mode.  Sulfate is the dominant product, as 
expected, at m/z = 96.96032.  The sulfonic acid can be seen at m/z = 161.00252. The 
substrate can still be seen at 113.01798. 
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4.3 Reaction Kinetics. 
 
Figure 4.5 shows rapid kinetics scans of the reaction mixture which shows 
activity at 260 nm and 360 nm.  The peak at 260 is consistently decreasing peak at 260, 
This peak which is attributed to λmax for methimazole, Figure 4.1 trace (a). Another peak 
of importance is at 360 nm, it commences after an induction period determined by initial 
conditions. This peak is attributed to ClO2
 
. The peak at 260 nm is at its lowest when that 
at 360 nm reaches its peak.  Chlorine dioxide color slowly faded after prolonged standing 
due to its decomposition and volatility.   In high acid conditions, the absorbance 
measured at 360 nm attained a transient peak which then slowly decreases to its final 
value, hinting some olligooscillatory behavior. 
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Figure 4.5:  Multiple scan of MMI oxidation by chlorite in aqueous acidic medium at 60 
seconds intervals. [MMI]0 = 3.00 X10
-4
 M, [ClO2
-
]0 =3.00 x10
-3
 M and               
[HClO4]0 = 1.00 x10
-1
 M 
 
Figure 4.6 shows the effect of MMI on the chlorite-MMI reaction.  Chlorine 
dioxide formation commences almost immediately after mixing.  In all traces shown in 
this figure, chlorite was in stoichiometric excess over MMI, that is; the ratio was over 
2:1.  The transient peak in chlorine dioxide absorbance is attained within 2 seconds.  If 
this reaction is monitored further, the chlorine dioxide will attain a minimum value which 
remains invariant for up to an hour.  The final chlorine dioxide concentration is 
determined by the excess chlorite concentrations.  This effectively involves the well-
known disproportionation of chlorite in acidic environments.
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Multiple scans of Methimazole oxidation by chlorite in aqueous acidic medium
                                                  at 60 seconds interval
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Traces were collected every 60 s reaction time intervals. [MMI]0 = 3 x 10
-4
 M, [ClO2
-
]0 = 3 x 10
-3 
M, 
and [HClO4]0 = 0.1 M. 
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 5ClO2
-
  +  4H
+
    →   4ClO2(aq)  +  Cl
-
  +  2H2O  (R4.2) 
 
 
 
 
Figure  4.6. Variation of [MMI]o  and its oxidation , Fixed [ClO2
-
] = 2.50 x10
-3
 M,  [H
+
] 
= 5.00 x10
-2
 and varied [MMI]  (a) 5.00 x 10
-4
 M, (b) 6.00 x 10
-4
 M, (c) 7.00 x 10
-4
 M, (d) 
8.00 x10
-4
 M  (e) 1.00 x10
-1
 M and (f ) 1.10 x 10 
-3
 M 
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Figure 4.7. Effect of [ClO2
-
]o variation on the reaction with MMI. Fixed:[MMI] = 1.00 
x10 
-3
 M, [H
+
] = 0.01 M and varied [ClO2
-
] = (a) 1.00 x 10
-2
 M,  (b) 2.00 x 10
-2
 M, (c) 
4.00 x10
-2
 M, (d) 6.00 x 10 
-2
 M and (e) 1.00 x10 
-1
 M. INaClO4 = 1.00 M. 
 
Figure 4.7 shows the variation of initial chlorite concentrations at a pH of 1.00.  
The reaction is much faster than those reactions run at pH 1.3 in Figure 4.6, above, and 
the transient peak of chlorine dioxide is attained much earlier.  The peak is also much 
sharper.  Figure 4.8 shows the complex dependence of the reaction on acid 
concentrations.  Lower concentrations gave a monotonic increase in chlorine dioxide 
concentrations within the 5 seconds observation window.  Higher acid concentrations 
gave oligooscillations.  Acid catalyzed a faster initial rate of formation of chlorine 
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dioxide.  Absorbance traces, for the range of acid concentrations studied, seemed to all 
converge at a specific absorbance value 1.3 seconds into the reaction.  It was not possible 
to determine the significance of this coherence since this could not be related to an 
isosbestic point: nothing else absorbs at 360 nm apart from chlorine dioxide.  Thus it 
could merely be a saturation point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  Effect of [H
+
]o variation on the reaction with MMI with ClO2
-
.  Fixed: 
[MMI] = 1.00 x10
-3
 M,  [ClO2
-
] =  2.50 x10
-3
 M, varied [H
+
] =  (a) 2.50 x10
-3
 M (b) 5.00 
x 10
-3 
 M, (c) 1.00 x10
-2
 M, (d) 3.00 x10
-2
 (e) 5.00 x10
-2
 M and 0.01 M. INaClO4 = 1.00 M. 
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4.3.1 Chlorine dioxide-MMI reaction kinetics 
 
The direct reaction of chlorine dioxide  with MMI was also studied.  With the 
observed oligooscillations in chlorine dioxide concentrations, it meant this reaction was 
directly relevant.  It appears the reactions that form and consume chlorine dioxide are 
approximately of the same order of magnitude in rates, with the dominance of each being 
determined by the presence of the relevant reagents.  If the chlorine dioxide – MMI 
reaction was much faster than the chlorite – MMI reaction, then one would observe an 
induction period followed by formation of chlorine dioxide, and in the opposite case, one 
would observe a monotonic increase in chlorine dioxide formation up to its final 
absorbance. However, what we see here is non-linear behavior.  Figure 4.9 shows the 
effect of varying chlorine dioxide concentrations.  Of note, traces, a to e, apart from trace 
f, all contain stoichiometric excess of MMI such that, at the end of the reaction, all 
chlorine dioxide would have been expended. The observed residual absorbance of 0.02 
units is derived from the other products in the reaction mixture.  Thus the reaction will 
appear to be rapidly shutting down due to contribution to the absorbance from the 
product.    
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Figure 4.9. Variation of [ClO2]o concentration and its effect on rate of reaction , Fixed 
[MMI] =  5.00 x10
-5 
M, and varied [ClO2]  (a) 5.00 x 10
-5
 M, (b) 6.00 x 10
-5
 M, (c) 7.00 
x 10
-5
 M, (d) 8.00 x10
-5
 M  (e) 9.00 x10
-5
 M and  (f ) 1.00 x 10 
-4
  M 
 
The direct reaction of chlorine dioxide and MMI appears to be very rapid in this 
unbuffered environment; essentially over in 200 msec.  Our stopped-flow instrument has 
a mixing time of 1.0 msec, and from the experimental traces observed in Figure 4.9, it 
appears the first electron transfer is too rapid to be observed.  For example, for trace f, we 
expect an initial absorbance of 0.110, and our observed initial absorbance is 0.088.  Thus 
the initial step of this reaction will involve a rapid adduct formation between the radical 
chlorine dioxide and the nucleophilic sulfur center of MMI, as shown below. 
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Scheme 4.1 Proposed MMI-Chlorite adduct formation and concomitant formation of 
sulfenic acid 
Figure 4.10 shows the variation of MMI concentrations. MMI is in stoichiometric 
excess in all these traces.  There is, progressively a decrease in observed initial 
absorbance of chlorine dioxide as initial MMI concentrations are increased, indicating the 
presence of an initial rapid step which is beyond the capabilities of our stopped-flow 
spectrophotometer. 
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Figure 4.10: Variation of [MMI]o  and their effect on rate of reaction, Fixed [ClO2] =  
5.00  x10
-5 
M, and varied [MMI]  (a) 2.50 x 10
-5
 M, (b)2.60 x 10
-5
 M, (c)2.70 x 10
-5
 M, (d) 
2.80  x10
-5
 M  (e) 2.90 x10
-5
 M  (f ) 5.00 x 10 
-5
  M 
 
Thus it becomes very difficult to determine an initial rate of reaction, except a 
lower limit rate constant with no statistical analysis nor error bars.   Both Figures 4.9  and 
4.10 suggest bimolecular kinetics with the reaction first order in both chlorine dioxide 
and MMI. 
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4.3.2 Chlorite-MMI reactions at λmax 260 nm. 
 
Absorbance traces at 360 nm show formation of chlorine dioxide due to  the MMI 
– Chlorite reaction.  Spectral scans in Figure 4.1 show an initially isolated peak for MMI 
at 260 nm.  Absorbance observations at this wavelength could show us the initial 
dependence of the reaction on MMI and chlorite, as well as the requisite initial rate.  We 
had initially evaluated an absorptivity of MMI at 260 nm of 11412 M
-1
 s
-1
.  Figure 4.11 
shows the dependence of MMI on the MMI – Chlorite reaction.  The reaction was run at 
0.25 M acid, and was over in about 2 s.  It was first order in MMI.   
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Figure 4.11:  Effect of [MMI]o variation on its  oxidation by  chlorite at 260 nm. [ClO
-
2,]  
=2.50 x 10
-3
 M,   [H
+
] = 0.25 M and varied  [MMI] =  (a) 1.40 x 10
-4 
M,  (b) 1.30 x 10 
-4
 
M,   (c) 1.20 x 10 
-4
 M,   (d) 1.10  x10-4 M,  (e) 1.00 x10 
-4
 M 
 
Figure 4.12 shows absorbance traces taken at 260 nm while varying chlorine 
dioxide.  These plots are significant: With MMI maintained at a constant initial 
concentration, one notices that the starting absorbance readings are invariant over the 
series of experiments undertaken.  This implies that our stopped-flow instrument is able 
to capture the whole reaction sequence, i.e. there is not initial rapid section of the reaction 
that is not within the mixing time limitations of the instrument. 
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Figure 4.12:  Effect of varying [ClO2
-
]o on oxidation of MMI at 260 nm  Fixed [MMI,]  
=1.2 x 10
-4
 M,   [H
+
] = 0.25 M and varied  [ClO2
-
] =  (a) 1.0 x 10
-3
 M,  (b) 1.5 x 10 
-3
,  
(c) 1.8 x 10 
-3
,   (d) 2  x10
-3
 M,  (e) 2.5. x10
-3
 M (f) 3.0  x10
-3
 M 
 
Although chlorite was in overwhelming excess over MMI, no pseudo-first-order kinetics 
are observed.  This is as a result of the residual absorbance derived from the products.  
Both Figures 4.11 and 4.12 delivered a bimolecular rate constant for the MMI – chlorite 
reaction of 3.02 ± 0.42 x 10
2
 M
-1
 s
-1
. 
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Figure 4.13: Effect of acid variation on oxidation of MMI. Fixed  [MMI,]  =1.30  x 10
-4
 
M,   [ClO2
-]
 = 0.25 M and varied  [H
+
] =  (a) 0.10 M,  (b) 0.20  M, (c) 0.30 M,  (d)0.40 
M,  (e) 0.50 M 
Figure 4.13 shows the acid dependence of the reaction.  Acid seems to have very little 
effect on the reaction.  Higher acid concentrations marginally increase the rate of 
reaction, however, it gives a higher residual absorbance at the end of the reaction.  
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4.4  Mechanism 
 
The almost instantaneous formation of chlorine dioxide implies that there is a 
rapid formation of HOCl in the initial phase of the reaction.  Hypochlorous acid is known 
to rapidly react with chlorite in acidic medium to form chlorine dioxide
114
: 
  2ClO2
-
  +  HOCl  +  H
+
  →  2ClO2(aq)  +  Cl
-
  +  H2O  R4.3 
Thus it would appear that the initial oxidation/reduction involved 2-electrons to produce 
HOCl and the oxidized form of methimazole, the sulfenic acid.  Assuming that 
methimazole can be represented as RSH, the enol form; the sulfenic acid can be 
represented as RSOH as represented in the  
  
Scheme 4.2: The keto and enol forms of MMI 
 
Scheme 4. 3: The initial oxidation scheme of MMI to form the sulfenic and S-oxide 
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RSH  +  ClO2
-
  +  H
+
  →   RSOH  +  HOCl     R4.4 
The sulfenic acid is known to be unstable and can either be further oxidized to the 
sulfinic acid in excess oxidant, or to the dimeric species in excess reductant. 
  RSOH + [O]  →  RSO2H     R4.5 
  2RSOH  →  RSSR  +  H2O     R4.6 
This has been confirmed by an experiment in which MMI is reacted with one equivalent 
of aqueous bromine.
62
  This will impart a 2-electron oxidation on MMI.  This should halt 
the oxidation at the sulfenic acid if the sulfenic acid is stable.  If the sulfenic acid is not 
stable, we would expect a series of sulfur oxo-acids. This has been thoroughly described 
in section 3.2.7.   
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4.4.1 Oxychlorine chemistry:   
Chlorine dioxide formation is so rapid.  Its formation is enhanced by the 
formation of a reactive species, HOCl.  There is however another intermediate species 
involved in the sequence. This was  identified as the asymmetric intermediate Cl2O2  
speciesc.
115,116
 
  ClO2
-
  +  HOCl  +  H
+
 ⇄   Cl2O2  +  H2O   R4.7 
  Cl2O2  +  2H
+
  +  2e
-
  ⇄   2HOCl    R4.8 
Addition of R4.7 and R4.8 gives quadratic autocatalysis in HOCl in excess ClO2
-
. 
 ClO2
-
  +  HOCl  + 3H
+
 + 2e
-
  →  2HOCl  +  H2O   R4.9 
Formation of HOCl thus exponentially increases the formation of more HOCl.  One can 
assume, then, that the major oxidizing species in the reaction medium is HOCl: 
 HOCl  +  RSH   →  RSOH  +  Cl
-
  +  H
+
    R4.10 
 HOCl  +  RSOH  →  RSO2H  +  Cl
-
  +  H
+
    R4.11 
 HOCl  +  RSO2H  →  RSO3H  +  Cl
-
  +  H
+
    R4.12 
 HOCl  +  RSO3H  + H2O  →  N-Methylimidazole  +  SO4
2-
  +   Cl
-
  +  3H
+
 
 R4.14 
As Cl
-
 builds up, the hydrolysis reaction of Cl2 becomes relevant: 
  HOCl  +  Cl
-
  +  H
+
  ⇄   Cl2  +  H2O   R4.15 
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The lack of gaseous chlorine observation indicates that the Cl2 – MMI is very rapid. 
4.4.2 Effect of chloride:   
 
There has been some  debate in oxychlorine kinetics on the reaction of chlorite and 
chloride:
117,118
 
 ClO2
-
  +  Cl
-
  +  2H
+
   →   2HOCl  R4.16 
 
 Figure 4. 14.  Effect of chloride ions on the oxidation of MMI . Fixed [MMI] = 1.0 x10
-3
 
M, [H
+
] = 2.5 x 10-3 M,  [ClO2
-
] = 2.5 x 10
-3
 and (a)  No Cl
-
 , (b) [Cl-] = 1.0 x10
-3
 M (c) 
2.0 x10
-3
 M, (d) 3.0 x10
-3
 M,  (e) 5.0 x 10
-3
 M.  There is minimal effect of chloride on the 
overall reaction. 
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It is clear from above experiment that, there is minimal effect of chloride on the overall 
reaction. 
There is a very viable and well-known analogue of reaction R4.16 involving bromous 
acid: 
  HBrO2  +  Br
-
  +  H
+
  →   2HOBr    R4.17 
Equilibrium of reaction R4.17 lies more to the right, with formation of HOBr enhancing 
the rate of reaction since, in all bromate oxidations, HOBr is the major oxidizing species.  
Thus bromate oxidations are catalyzed by addition of bromide.   Figure 4.14, however, 
shows that chlorite has little effect on the reaction, thus conforming that Reaction R18 is 
essentially inert. 
 
4.4.3 Effect of acid:  
 
Both chlorite – MMI and chlorine dioxide – MMI reactions show complex 
dependence on acid.  This is due to effectively two acid-base equilibria that are relevant 
in the reaction mixture.  The first is the dissociation constant of chlorous acid: 
  ClO2
-
  +  H
+
  ⇄    HClO2; Ka
-1
  R4.18 
And the second involves protonation of the thiol center: 
  RSH  +  H
+
   ⇄  RSH2
+
; Kb            R4.19 
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The protonation can also occur with the keto-form of MMI in which the 5-membered 
imidazole ring can be represented as R1R2: 
  R1R2C=S  +  H
+
   ⇄   [R1R2C=S-H]
+
  R4.20 
The ideal situation for the fastest initiation, reaction R4.4-type reaction would involve the 
protonated thiol with the unprotonated Cl(III) species: 
 ClO2
-
  +  RSH2
+
   →   HOCl  +  RSOH   R4.21 
Reaction R4.21, however, is an unlikely combination, given that pKa of chlorous acid is 
1.72.  Low pH conditions will have negligible concentrations of ClO2
-
 and high pH 
conditions will have negligible concentrations of protonated MMI.  Thus from the 
combination of reaction R4 with equilibria R4.18 and R4.19: 
 HClO2  +  RSH  →  RSOH  +  HOCl    R4.20 
 HClO2  +  RSH2
+
  →  RSOH  +  HOCl  +  H
+
  R4.21 
The experimentally observed acid dependence can be explained as following. At pH 
conditions less than 1.0; virtually all Cl(III) species will be in HClO2.  The thiol 
protonation scheme is very rapid in either direction.  Thus there is only minimal acid 
catalysis in the chlorite – MMI reaction between pH 1.0 and 0.301; as is shown in Figure 
4.12.  However, all oxychlorine reactions proceed faster with acid, especially the 
composite reaction for the formation of chlorine dioxide, reaction R4.3.  Thus, at the 
initial part of the reaction, high acid would catalyze formation of chlorine dioxide.  After 
the initiation reaction(s) that form HOCl, the HOCl can proceed to oxidize MMI and its 
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sulfur oxo-acids, R4.10 to R4.11, or proceed to oxidize chlorite to chlorine dioxide.  
Kinetics data suggests that these two sets of reactions, those that form and consume 
HOCl are of approximately equal magnitude, hence the oligooscillatory behavior 
observed in chlorine dioxide formation.  Acid will catalyze formation of HOCl much 
more rapidly than the oxidation of MMI by HOCl.  HOCl, being an electrophile, reacts 
faster with the unprotonated thiol.  
 
4.4.4 Reaction of chlorine dioxide and MMI.  
 
The direct reaction of chlorine dioxide is initially slower than reactions that 
produce chlorine dioxide; hence there is the immediate and almost instantaneous 
production of chlorine dioxide in the chlorite – MMI reaction.  Acid has a minimal effect 
on this reaction.  Bimolecular kinetics suggest the first step of the reaction is an initial 
adduct formation between chlorine dioxide and MMI.  Chlorine dioxide is a radical 
species, and the first step is the addition of an electron to the odd-electron deficient 
chlorine center to a more stable species; the Cl(III) chlorite: 
  ClO2  +  e
-
   →   ClO2
-
  ;  E0 = 0.94 V    R4.22  
Chlorite will then continue with the oxidation of the substrate. 
  R1R2C=S  +  ClO2   ⇄   [R1R2C=S-ClO2]    R4.23 
 [R1R2C=S-ClO2]  +  ClO2  +  H2O  → R1R2C-SOH  +  2ClO2
-
  +  2H
+
 R4.24 
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This reaction is solvent assisted; with the reaction faster in protic solvents and sluggish in 
solvents such as acetonitrile.
119
  Thus for bimolecular kinetics to prevail, the solvent 
dissociates the adduct in reaction R4.24 first before addition of the second chlorine 
dioxide molecule.  If the order was reversed, third order kinetics would have been 
observed.  The adduct will have a partial positive charge, which can be attacked by a 
nucleophile.  This would give an unstable Cl(II) intermediate which can rapidly react, in 
a non-rate-determining manner, with chlorine dioxide, to form chlorite. 
[R1R2C=S-ClO2]  +  H2O  ⇄   [R1R2C=SOH]
+
  +  HClO2
-
 ; rds  R4.25 
HClO2
-
  +  ClO2  →  2ClO2
-
  +  H
+
      R4.26 
The [R1R2C=SOH]
+
 intermediate can lose a proton to give an S-oxide or a sulfenic acid. 
 
4.4.5 Oligooscillations  
 
Figures 4.6 and 4.7 all show that chlorine dioxide attains a transient maximum 
before decaying to its final value.  Rate of chlorine dioxide production is dependent on 
the rate of formation of HOCl since subsequent formation of chlorine dioxide is 
autocatalytic in HOCl.  Figure 4.7 reflects this logic.  Higher acid concentrations display 
a higher rate of formation of chlorine dioxide. Lower acid concentrations display a lower 
chlorine dioxide production rate such that the concentrations of chlorine dioxide do not 
‘over-shoot’ its expected stoichiometric concentration and a monotonic rate of formation 
is observed as in trace (a) in Figure 4.7.  Figure 4.6 echoes the same logic. Lower chlorite 
85 
 
concentrations display a monotonic rate of chlorine dioxide formation (trace (a) in Figure 
4.6) due to the lower rate of formation of HOCl and subsequently chlorine dioxide. 
4.5. Overall reaction scheme.  
 
Table 5.1 shows the full set of reactions involved in this reaction mixture.  There 
are three oxidizing species in the reaction mixture: Cl(III), ClO2 and HOCl.  There are 4 
possible reducing species: MMI, the sulfenic, sulfinic and sulfonic acids, sulfite and 
Cl(III). Chlorite, Cl(III), whether in the protonated or unprotonated forms, acts as either 
an oxidizing agent (for the substrate), or a reductant (for HOCl to form chlorine dioxide).  
Table 5.1 encompasses all three possible reactions: ClO2
-
 - MMI; ClO2 – MMI and ClO2
-
 
- HOCl reactions.  The table assumes all oxidation reactions, except those involving 
purely only oxychlorine species among themselves, are irreversible.  Most of the kinetics 
of the oxychlorine species are well known.  Those involving MMI oxidations were 
estimated in this study.  The initiation reactions that produce the reactive species HOCl 
are represented by reactions M4 to M6.  The highly unlikely combination of unprotonated 
ClO2
-
 and the protonated MMI was not included in this scheme.  The autocatalysis 
involves reaction M7 in combination with any of reactions M9, M10 and M11.   With 
establishment of HOCl as the autocatalytic species, after the initiation reactions, one can 
use HOCl as the sole oxidizing species with very little loss in accuracy.  This implies 
addition of reactions M17 to M21 does not improve the model except when there is 
overwhelming excess of chlorite. Oxidation of the sulfonic acid could be through the 
entropy-driven composite reaction M19, or through the 2-step process M22 and M23.  
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HSO3
-
 is labile and easily oxidized to sulfate even by the mildest oxidizing agents; thus 
just the use of reaction M17.  Chlorine dioxide reactions are represented by reactions 
M24 to M28.  The activities of aqueous chlorine dioxide, at various low pH conditions, 
however, were not known.  Some of the wavy traces observed, e.g. Figure 4.6 and 4.7 
were derived from formation of gaseous ClO2.  This precluded a successful modeling of 
the reaction scheme. 
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Table 4.1.  Chlorite – Chlorine Dioxide – MMI reaction. 
 
No. Reaction 
M1 ClO2
-
 + H
+
 ⇄  HClO2 
M3 R1R2C=S + H
+
 →  [R1R2C=S-H]
+
 
M4 ClO2
-
 + R1R2C=S  +  H
+
   → R1
'
R2CSOH + HOCl 
M5 HClO2 + R1R2C=S   → R1
'
R2CSOH + HOCl 
M6 HClO2 + [R1R2C=S-H]
+
 → R1
'
R2CSOH + HOCl + H
+
 
M7 ClO2
-
 + HOCl + H
+
  ⇄  Cl2O2 + H2O 
M8 Cl2O2 + ClO2
-
  ⇄  2ClO2(aq) + Cl
-
 
M9 Cl2O2 + R1R2C=S + H2O  →  R1
'
R2CSOH + 2HOCl 
M10 Cl2O2 + R1
'
R2CSOH + H2O  →  R1
'
R2CSO2H + 2HOCl 
M11 Cl2O2 + R1
'
R2CSO2H + H2O  →  R1
'
R2CSO3H + 2HOCl 
M12 Cl2O2 + R1
'
R2CSO3H + H2O  →  R1R2C=O  + SO4
2-
 + 2HOCl  + 2H
+
 
M13 HOCl + R1R2C=S  →  R1
'
R2CSOH + H
+
 + Cl
-
 
M14 HOCl + R1
'
R2CSOH  →  R1
'
R2CSO2H + H
+
 + Cl
-
 
M15 HOCl + R1
'
R2CSO2H  →  R1
'
R2CSO3H + H
+
 + Cl
-
 
M16 HOCl + R1
'
R2CSO3H  + H2O  →  R1R2C=O  + SO4
2-
 + 3H
+
 + Cl
-
 
M17 ClO2
-
 + R1
'
R2CSOH  +  H
+
  → R1
'
R2CSO2H + OCl
-
 
M18 ClO2
-
 + R1
'
R2CSO2H → R1
'
R2CSO3H + OCl
-
 
M19 ClO2
-
 + R1
'
R2CSO3H + H2O → R1R2C=O  + SO4
2-
 + OCl
-
 + 2H
+
 
M20 HClO2 + R1
'
R2CSOH → R1
'
R2CSO2H + HOCl 
M21 HClO2 + R1
'
R2CSO2H → R1
'
R2CSO3H + HOCl 
M22 R1
'
R2CSO3H + H2O  → R1R2C=O + HSO3
-
 + H
+
 
M23 HSO3
-
 + HOCl →  SO4
2-
 + 2H
+
 + Cl
-
 
M24 ClO2(aq) + R1R2C=S ⇄  [R1R2C=S:ClO2] 
M25 [R1R2C=S:ClO2] + ClO2(aq) + H2O   R1
'
R2CSOH + 2H
+
 + 2ClO2
-
 
M26 ClO2(aq) + R1
'
R2CSO2H ⇄  [R1
'
R2CSO2H:ClO2] 
M27 [R1
'
R2CSO2H:ClO2] + ClO2(aq) ⇄ R1
'
R2CSO3H + 2H
+
 + 2ClO2
-
 
M28 ClO2 + HSO3
-
 ⇄ [O2ClSO3H
-
] 
M29 2 R1
'
R2CSOH ⇄ R1
'
R2CSO2H + R1R2C=S 
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4.6. Conclusion 
 
MMI is oxidized by chlorite and chlorine dioxide all the way through to 
desulfurization.  Chlorite oxidation of MMI produces negligible amounts of the S-oxide 
(see Figure 4.4) and no evidence of the sulfinic acid.  The sulfonic acid is a major 
pathway of oxidation before formation of sulfate and N-methylimidazole.  The lack of 
observation of substantial amounts of the sulfenic and sulfinic acids in the ESI spectrum 
does not preclude their presence in the pathway and mechanism: it just means that these 
oxoacids are very unstable and are easily oxidized further.       
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CHAPTER FIVE  
 Electrochemical and Enzymatic in Vitro Studies, of 6-propyl-2-thiouracil 
5.1. Introduction 
 
6-propyl-2- thiouracil (PTU) is an  antithyroid drug that was introduced close to 
seventy years ago.
86
 This drug is effective in the  treatment and management of  Grave’s 
disease, an autoimmune diseases mediated by thyroid stimulating immunoglobulins; 
resulting in  hyperthyroidism, which is over production of thyroid hormones.
120
 It works 
by inhibiting the activity of thyroid peroxidase and blocks the conversion of thyroxine 
(T4) to triidothyronine (T3). The action of PTU may partly depend on its ability to 
function as a thiol as shown by tautomer forms below.
121
 
 
Figure 5.1 Tautomers of PTU 
 Although effective, PTU has been associated with rare but severe idiosyncratic 
toxicity, characterized by; skin reactions, agranulocytosis, aplastic anemia, hepatitis and 
cholestasis. 
85,86
 PTU is identified as being the third most frequent cause of drug-induced 
liver transplant in the United States.
122
 In 2008, a panel of experts extensively reviewed 
adverse events reports and case reports of PTU-induced liver failure and deaths. They 
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recommended that PTU should not be used as first line of therapy in Grave’s disease.
123
  
In 2010 the Food and Drug Administration (FDA) issued a black box warning about 
severe liver injury associated with treatment using PTU. Hepatotoxicity of therapeutic 
drugs is not a new phenomenon in drug therapy.   
A number of drugs have already been withdrawn from market after cases of 
severe toxicity where noted. Bioactivation of  drugs resulting in reactive metabolites is 
considered as the initial step towards drug induced organ damage.
124
 Presumably the 
hepatotoxicity associated with PTU is due to its reactive metabolites in the liver, these 
could be radicals or electrophiles. However, as of now,  there are  no reports on the PTU 
reactive metabolite(s) formation in liver, and the role of the formed intermediates in the 
hepatotoxicity induced by this drug is ambiguous.
125
 There has been a variety of 
metabolites observed from PTU metabolism. Two oxidation systems were examined for 
the oxidation of PTU.  Metabolites generated by electrochemical oxidation were 
compared to those that were identified from microsomal oxidation. Slight differences 
were noted in the identity of the metabolites. 
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5.2 Results and discussion  
5.2.1  Electrochemical oxidation of PTU in basic medium 
 
Electrochemical oxidation of PTU was carried out using the arrangement shown in figure 
2.4. Initial experiments were carried out in the absence of trapping agents. Control 
experiments were initiated with the cell turned off at 0 potential.  Figure 5.2 clearly  
 
Figure 5.2  ESI (-) MS, with cell turned off 0 mv obtained for 0.1 mM PTU in ammonium 
in 20 mM ammonia, 20% MeOH, pH 10, Flow rate 10 µL/min.  
 
shows a clean ESI-spectrum of PTU that was obtained in the negative mode. The only 
peak that is evident from the spectra above is the substrate PTU with m/z 169.04 
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The presence of a single peak from the solvent-electrolyte mixtures shows that there were 
no any other reactions or contaminants prior to the electrochemical oxidation. 
Contaminants as well as other reactions in the electrolyte mixture, are usually confused 
for modifications that might take place on the compound of interest.  As such, any 
products that emerged when the reaction was initiated by applying potential could thus be 
attributed to transformations due to oxidation of PTU in the electrochemical cell. 
 When the cell was turned on, the voltage was gradually increased with a ramp of 100 
mV each time. There was emergence of additional peaks at 400 mV. This potential was 
enough to initiate oxidation of PTU to a disulfide and sulfinic acid, as shown in figure 5.3 
below. PTU disulfide was the dominant peak in both acidic and alkaline medium. 
However, in acidic medium there were many spurious peaks that could not be easily 
assigned to anything.   
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Figure 5.3. ESI-MS spectra generated with the cell potential at 400 mV.  
 
Figure 5.3 shows a strong peak of PTU-disulfide, which is the major product of 
oxidation at the given potential of 400 mV. Dimeric species from thiols are usually 
unreactive compared to parent thiols, hence they accumulate.  Surprisingly, the 
electrochemical oxidation of PTU was achieved at very low potentials, compared to what 
has been reported previously in literature. Sartori et al, reported higher electrode   
potentials of  1.42 V  for oxidation of  PTU to its dimer using  cyclic voltammetry.
126
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Electrode potential (Em) is pH-dependent, it has been shown that it decreases with   
approximately 0.06 V/pH, for a simple thiol such as glutathione. Therefore, as the pH is  
increased, the potential required to effect oxidation decreases.
127
  The data below points 
out the possibility of two competing reaction pathways. Thiol oxidation can proceed 
through two competing pathways. Abstraction of a single electron is relatively easy 
leading to a thiyl radical. The two electron pathway, results in formation of sulfenic acid. 
These two intermediates participate in further reactions resulting in metastable 
products.
128
 Thus the thiyl radical might initiate chain reactions that results in a disulfide. 
This is a coupled-proton electron transfer process resulting in a radical that dimerizes to a 
disulfide as shown in scheme 5.1 below.   
 
 
 
Scheme 5.1 Proposed oxidation scheme for PTU and its dimerization to a disulfide 
compound. 
 
There is a relatively weak peak at   m/z 201 which shows a sulfinic acid. In theory 
one would expect to observe the S-oxides of PTU in the mass spectrum.   Thiols are  
known to undergo oxidation to sulfenic acid  which  further  oxidizes  to  more stable 
sulfinic and sulfonic acids respectively,
129,130
 as  seen in the  equation  below.   
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RSH   RSOH   RSO2H         RSO3H…….. (R5.1) 
Thiol   sulfenic acid  sulfinic acid  sulfonic acid 
There is no evidence of formation of sulfenic acid, or the S-oxide in the spectrum. The 
sulfenic acid may transform to its more stable form of an S-oxide.
62
 However, sulfenic 
acids exhibit potent electrophilic and relative weak nucleophilic reactivity.
131
 Thus in 
small molecules such as PTU, this dual behavior can lead to self-condensation in which 
one sulfur atom functions as a nucleophile and the second as an electrophile to yield a 
thiolsulfinate ester shown below  
 
….. (R.5.2) 
 
The self-condensation reaction is facilitated by intermolecular hydrogen bonding.  At a 
pH > 8, which is the case in this series  experiments, the thiolsulfinate esters 
disproportionate to form salts of sulfinic acid and disulfide.
132
 This reaction can thus 
explain both the presence of sulfinate and the dimer observed in figure 5.3. Trapping 
experiments were also conducted in PTU oxidations. Unlike in oxidation of methimazole, 
there were no conjugates that formed between PTU and nucleophiles.  Presumably the 
reaction proceeds through formation of the dimer. This dimer then would further be 
oxidized to sulfinic acid. Regardless of which pathway dominates, both mechanisms have 
potential to result in reactive intermediates 
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5.2.2 Effect of oxidation potential  
 
 An analysis of the ESI spectrum collected at higher oxidative potentials of 800 
mV shows two additional peaks that were observed on the mass spectrum. Figure 5.4 
show that sulfur was fully oxidized, from -2 to +6, to yield sulfate (SO4
2-
) shown, with 
m/z 96. Effluent from the cell was reacted with barium chloride, resulting in formation of 
BaSO4.  There was no evidence of formation of PTU-sulfonic acid from the ESI mass 
spectra. Hydrolysis of sulfinic acid, should result in the cleavage of the C=S bond to give 
a urea-type residue, R1R2C=O and an unstable sulfur species HSO2
-
 . HSO2
-
 is readily 
oxidized to bisulfite (HSO3
-
).  
 
HSO2
-
 + H2O    HSO3
-
  +  2H
+
  +  2e-    R5.3 
 
HSO3
-
 is in turn easily hydrolyzed to sulfate. One would expect a significant amount of 
the urea type organic residue if hydrolysis was the major pathway. However, only traces 
(propyl uracil)  at m/z 153 and an unidentified metabolite with m/z 135 were observed.  If 
this organic residue is not stable; it would further hydrolyze through ring opening giving 
small fragments. A decrease of 32 amu, is apparent from the initial mass of substrate.  
The exact mechanism from the sulfinic acid to sulfate and an organic residue can only be 
speculative, but involves no further oxidation past the formation of sulfate. Non-solvent 
assisted cleavage of C-S bond, which is either heterolytic or homolytic cleavage, should 
result in loss of sulfur as sulfite and sulfite radical anion respectively from sulfinic 
acid.
133
  The organic residue observed is shown with the peak at m/z of 137, thus this is  
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6-propyl-2, 3-dihydropyrimidin-4(1H)-one. The spectrum below still shows the dimer 
m/z 168 is the symmetrical PTU dimer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. ESI-MS spectra generated with the cell potential at 800 mV.  
 
The one-electron pathway, resulting in thiyl radicals appears to be the most dominant 
mechanism here. Radicals play a very important role in induced oxidative stress and 
subsequent liver injury. Waldhauser and co-workers investigated the oxidation of PTU in 
activated neutrophils.  PTU was observed to be oxidized  by myeloperoxidase,
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resulting in sulfite as one of the products, as indicated above, this can be further oxidized 
to sulfate. If PTU desulfurization involve forming sulfite radical, one would expect it to 
undergo further reactions which may or may not lead to reactive metabolites.  
 It has been shown that sulfite and sulfite radicals are oxidized by 
myeloperoxidase to free radicals. These prooxidant  radicals , such as the reactive sulfur 
trioxide (SO3
•−
), peroxymonosulfate (−O3SOO
•
), and sulfate (SO4
•−
) anion radicals have 
capacity to damage proteins and oxidize them to protein radicals, with consequences of 
allergic reactions.
134
 Whereas some studies reported that there have been no reactive 
metabolites formation in the liver. Some intermediates e.g., 6-propyl-2,3-
dihydropyrimidin-4(1H)-one , (propyluracil) and other unidentified metabolites, with 
prooxidant radicals  were  echoed  in electrochemical system.  Some of the intermediates 
have been proposed but have not been observed in previous in vivo and in vitro studies. 
Radicals can also generate toxic effects through oxidative stress without forming covalent 
adducts with biomolecules.
135
   This forms the basic framework for the danger hypothesis 
that leads to idiosyncratic toxicities. 
 
5.3 In vitro enzymatic oxidation of PTU 
 
The metabolism of PTU was studied based on standard in vitro technique, 
involving incubation of the target compound with liver microsomes. The experiments 
here were performed using human microsomes. The results obtained from the liquid 
chromatography separation with mass spectrometry detection are shown in Figure 4.5. 
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The oxidation of PTU with microsomes was complex. Identification of the products from 
metabolism was complicated by the presence of biological matrix and a range of possible 
metabolites.  
 
 
Figure 5.5. LC-MS chromatograms from metabolites generated by incubation with 
human liver microsomes (HLM) 
Although not quite abundant figure 5.6 shows spurious peaks on the ESI-spectra, 
some of them where unidentified. However, this observation does not really point to an 
inferior technique. Instead it does show that a variety of metabolites a possible from 
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biological oxidations versus EC-MS. Figure 5.5 shows the chromatogram, extracted from 
ion filtering using Xcalibur software. Retention time of the 14.30 peak shows the 
unconverted substrate PTU, with m/z 171.13 shown in figure 5.6 below.  Another peak 
on the chromatogram, with retention time of 5.81 was associated with the unconverted 
substrate; this could be due to tautomer of PTU, resulting in a more polar ion form of 
PTU. This analysis is further complicated by the appearance of another small peak that 
co-eluted at this same retention time. The peak had a jump of 16 amu from the substrate, 
thus  [M + O + H] with at m/z 186.22, a putative PTU S-oxide. The relatively low 
abundance of the peak, appears to show a transient molecule that is derived from unstable 
sulfenic, moreover it is fleeting towards sulfinic and sulfonic acids.  In this biological 
matrix, the reactive sulfenic acid can react with the protein components of microsomes. 
Usually after centrifugation, the protein pellet will sediment and is not analyzed in LC-
MS analysis, hence a diminished peak of the remaining metastable S-oxide can be 
observed. Its polarity also fits very well to the assigned retention time.  
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Figure 5.6 ESI (+) mass spectrum showing product of oxidation from microsomal 
incubation. 
Interestingly, hepatotoxicity due to PTU has been known, but  it is surprising that, there 
have not been a lot of studies dedicated to the oxidation of PTU using microsomes. Most 
of the studies conducted used peroxidases as oxidants, and as such, there have not been 
known reactive metabolites produced from microsomes. Studies on the oxidation of PTU 
with  activated neutrophils showed that PTU-disulfide, PTU-sulfite/sulfinic acid, and 
PTU-sulfate/sulfonic acid  were the major products of oxidation.
110
.  The toxicity of 
thionamides, such as ethionamide has been associated with their bioactivation to reactive 
S-oxides.
136,137
 Therefore, hepatotoxicity due to PTU may also arise from the observed S-
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oxide; this electrophilic metabolite has the capacity to bind to liver cellular 
macromolecules resulting in drug damage to cells.  
 
5.3.1 Oxidation mechanism 
 
Metabolism by microsomes involves primarily the flavin-containing 
monooxygenases (FMO’s) and the CYP450 group of enzymes.  FMO’s are a family of 
drug-metabolizing enzymes that use FAD, NADPH and molecular oxygen to catalyze the 
oxygenation of a large number of xenobiotics  containing ‘soft’ nucleophiles such as 
sulfur, phosphorus and nitrogen.
138,139
   
 
 
 
 
Scheme 5.2 Proposed reaction scheme for PTU metabolism in microsomes. 
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The scheme above shows a simple mechanism for oxidation of PTU in microsomes. 
FMOs convert xenobiotics into polar metabolites by adding oxygen so that they can 
subsequently be easily eluted through the kidneys.
140
  While initially thought to be a 
single enzyme; FMO’s are now known to contain at least 11 isoforms, with 5 of them 
having been characterized to date.
141,142
  It has been reported that FMOs oxidize 
thionamides and thiourea functional groups to intermediate metabolites of sulfenic 
(RSOH) and sulfinic (RSO2H) acid which are responsible for deactivating CYP450 
enzymes.
143,144
 As mentioned earlier on, sulfenic acid is a very unstable intermediate, 
giving rise to metastable S-oxide.  In presence of excess oxidative power, the S-oxide and 
sulfinic acid will further be oxidized to sulfonic acid, as shown in scheme 5.2. 
The standard procedure for trapping reactive metabolites was also carried out 
using glutathione and n-acetyl cysteine as trapping agents. There were no detectable 
conjugates, in reactions of PTU. Sulfenic acid precedes formation of S-oxide and is very 
reactive to be able to react with thiol. However, even if the intermediates were formed, 
their conjugation with nucleophiles is not always spontaneous as in the case of MMI-
acetylcysteine, sometimes it requires enzymes, such as glutathione transferase which can 
facilitate conjugation.  
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Figure 5.7 ESI (+) MS spectra showing sulfinic acid and sulfonic acid as products of 
oxidation of PTU.  
 
PTU is less polar as compared to its products of oxidation, which co-eluted within 
1.95 and 2.06 minutes. Figure 5.7 shows 6-propyl-2-thiouracil sulfinic acid (PTU-SO2H) 
m/z 203.04, 6-propyl thiouracil sulfonic acid (PTU-SO3H)  m/z 218.94, and its sodium 
adduct m/z 240.09 as the major products of microsomal oxidation. These are stable 
oxides for oxidation of PTU.  PTU-sulfonic acid/sulfonate, at m/z 218.94, [M +3O +H
+
] 
and 240.09, [M +3O +Na
+
] exist as a zwitterion form before adducted to a proton or 
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sodium respectively. Microsomal oxidations were carried out in a pH of 7.4, close to 
neutral pH, and thus it can afford such neutral structures.  Molecules with such structure 
have been observed from X-ray data. Chigwada et al,
75
 showed the existence of this  
putative sulfonic acid zwitterion for tetra methyl thiourea sulfonic acid  (TTTU-SO3-), 
figure 5.8 a.  Figure 5.8 b shows putative the molecular ion as observed in ESI spectrum 
at m/z 240.02. 
 
 
  
(a)                                                                      (b) 
 
Figure 5.8 Putative zwitterion structures     
 
Figure 5.7 shows undefined metabolite at m/z 196.96. This shows some of problems that 
arise from microsomal oxidations. The matrix contains different endogenous material 
which can co-elute with compounds of interests. Contrary to this, it also shows the 
diversity of metabolites that can be obtained from microsomal oxidations.   
  
106 
 
5.3.2 Comparison of electrochemical and biological metabolism. 
 
There were variations in the nature and type of metabolites that have been 
observed from electrochemical oxidation of the PTU compared to what has been 
observed and  reported in biological studies.
145
  Both Figures 5.6 and 5.7 shows some 
unidentified peaks e.g., the peak with m/z 196 could not be assigned to any metabolite in 
the mixture. The electrochemical process is a ‘cleaner’ oxidation environment than that 
afforded by microsomes. Thus the electrochemical oxidation platform involves the most 
easily oxidizable part of the molecule without any regard to other parameters present in 
bimolecular activations such as stereochemistry.  
Oxidation of thiols through formation of their disulfides is relatively easy, 
compared to two electron process for the formation of S-oxide. Contrary to the EC-MS 
system, microsomal oxidations show non competing reaction pathways. Successive 
formation of sulfo-oxo acids is through a two electron transfer mechanism by FMO S-
oxygenation. Microsomes contain CYPs as well, which participates in functionalization 
reactions; as such one would expect a variety of metabolites. However, there are some 
other factors that might prevent this e.g., thionaamides are known to be enzyme 
inhibitors,
146
 this has large bearing on the nature of products that can be obtained from 
their biological oxidation using microsomes.  The kinetics for the EC-MS two electron 
mechanism are quite sluggish. Electron-withdrawing groups such as oxygen in the ring 
for PTU may reduce the nucleophilicity nature of S atom on the thiolate ion, making it 
difficult to abstract a second electron.  A comparison of EC-MS oxidations to microsomal 
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oxidations shows there is a physiological gap between the isolated microsomes and 
electrochemical cells. Nevertheless, there were similarities in type of metabolites 
obtained from EC-MS with those obtained using peroxidase enzymes as indicated earlier 
on. Differences in metabolites may be attributed to experimental conditions.   
 
5.5 Conclusion 
 
 Bioactivations of sulfur-based drugs have always been difficult to determine. 
PTU oxidation is generally complex, characterized by free radical and two electron 
process mechanism in electrochemistry and microsomal oxidations respectively.  PTU 
oxidation resulted in a range of metabolites, the absence of conjugates in either system, 
does not preclude formation of reactive metabolites. The kinetics of that step was much 
faster, such that the metabolites were not captured. However, results show that an S-oxide 
which is electrophilic and hepatotoxic is produced in liver microsomes. Toxicity of PTU 
may be attributed to this reactive metabolite. Moreover, the mechanism entails two 
pathways which might be involved in toxicity due to PTU. EC-MS techniques 
complement the microsomes and is quite informative in evaluation of toxicities from 
drugs, as it gives an alternative explanation to observed phenomena. 
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